<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-22710" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Gross and Microscopic Hematuria</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Leslie</surname>
            <given-names>Stephen W.</given-names>
          </name>
          <aff>Creighton University School of Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Hamawy</surname>
            <given-names>Karim</given-names>
          </name>
          <aff>Lahey Health</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Saleem</surname>
            <given-names>Muhammad O.</given-names>
          </name>
          <aff>Augusta University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Stephen Leslie declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Karim Hamawy declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Muhammad Saleem declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>29</day>
          <month>2</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-22710.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Hematuria, defined as the abnormal presence of blood in urine, presents in 2 primary classifications: gross and microscopic. Gross hematuria refers to visible blood in urine, while microscopic hematuria indicates red blood cell (RBC) detection through urinalysis or urine microscopy without apparent visual blood. Hematuria evaluation encompasses a broad spectrum of etiologies, with malignancy being a critical consideration, especially in patients with predisposing factors. A thorough assessment involves history-taking, physical examination, imaging, and laboratory tests.&#x000a0;Furthermore, risk stratification based on various parameters, including age, smoking history, RBC count, and prior episodes of hematuria, is essential in guiding management. Risk-appropriate evaluations are recommended to ensure timely detection and management of underlying pathology, particularly urological malignancies.&#x000a0;This activity for healthcare professionals is designed to enhance the learner's competence when managing gross and microscopic hematuria, equipping them with updated knowledge, skills, and strategies for timely identification, effective interventions, and improved coordination of care, leading to better patient outcomes.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Differentiate gross hematuria and microscopic hematuria.</p></list-item><list-item><p>Implement evidence-based protocols for the evaluation of patients with gross and microscopic hematuria.</p></list-item><list-item><p>Select optimal treatment strategies for a patient with gross and microscopic hematuria.</p></list-item><list-item><p>Collaborate with interprofessional healthcare teams to appropriately care for patients with hematuria.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=22710&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=22710">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-22710.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Hematuria is defined as the abnormal presence of blood in the urine. It is one of the most commonly diagnosed urological disorders, accounting for over 20% of all urological evaluations.<xref ref-type="bibr" rid="article-22710.r1">[1]</xref><xref ref-type="bibr" rid="article-22710.r2">[2]</xref>&#x000a0;While there are many classifications of hematuria (eg, intermittent or constant, glomerular or nonglomerular, symptomatic or asymptomatic), the most clinically useful is gross or microscopic (ie, microhematuria). Gross hematuria refers to visible blood in the urine. Microhematuria is the detection of urinary red blood cells (RBCs) on a dipstick or by microscopic urinalysis, though the visual appearance of the urine is normal.</p>
        <p>The minimum criteria used by the 2020 American Urological Association Microhematuria Guideline to diagnose microhematuria is the unexplained finding in an uncentrifuged specimen on microscopic evaluation of &#x02265;3 RBC/HPF.<xref ref-type="bibr" rid="article-22710.r1">[1]</xref><xref ref-type="bibr" rid="article-22710.r3">[3]</xref><xref ref-type="bibr" rid="article-22710.r4">[4]</xref>&#x000a0;This guidance has been established due to the relatively high incidence of false positives and negatives when using dipsticks alone.<xref ref-type="bibr" rid="article-22710.r1">[1]</xref><xref ref-type="bibr" rid="article-22710.r5">[5]</xref>&#x000a0;Blood from recent urological procedures, urinary tract infections (UTIs), and contamination from rectal or vaginal bleeding must be excluded.&#x000a0;In one study, only 41% of the patients diagnosed with microscopic hematuria by dipstick by primary care clinicians had microscopic analysis. Of those with microscopic analysis, only 24% had &#x0003e;3 RBC/HPF. This suggests that improved education regarding the definitions of hematuria would be useful to avoid unnecessary testing and referrals.&#x000a0;Some sources recommend using the more stringent criteria of at least 2 or even 3 confirmed microscopic findings of hematuria.<xref ref-type="bibr" rid="article-22710.r5">[5]</xref> In such cases, where only a single finding of microscopic hematuria has been detected, periodic follow-up urinalyses for at least a year are suggested if no further workup is conducted after the initial diagnosis.<xref ref-type="bibr" rid="article-22710.r5">[5]</xref><xref ref-type="bibr" rid="article-22710.r6">[6]</xref><xref ref-type="bibr" rid="article-22710.r7">[7]</xref>&#x000a0;</p>
        <p>Microscopic hematuria can be further subdivided into symptomatic microhematuria, asymptomatic microhematuria with proteinuria, which is suggestive of glomerular disease, and asymptomatic microhematuria without proteinuria, which suggests possible urothelial malignancy.&#x000a0;Microscopic urinalysis can also identify urinary infections and pertinent urinary sediment not detected by dipstick (eg, crystals and casts) that can help diagnose the underlying pathology. The absence of microscopic RBCs in dipstick-positive urine samples suggests myoglobinuria, hemoglobinuria from lysed erythrocytes, or some other cause of pseudohematuria.<xref ref-type="bibr" rid="article-22710.r5">[5]</xref><xref ref-type="bibr" rid="article-22710.r8">[8]</xref>&#x000a0;A microscopic examination of the urinary sediment must always confirm a presumptive diagnosis of microhematuria by dipstick.<xref ref-type="bibr" rid="article-22710.r1">[1]</xref><xref ref-type="bibr" rid="article-22710.r5">[5]</xref><xref ref-type="bibr" rid="article-22710.r9">[9]</xref>&#x000a0;The most severe and devastating consequence of hematuria is malignancy. Many classifications exist to stratify patients into low-, intermediate-, and high-risk; a commonly used and validated system is the 2020 American Urological Association Guideline on Microhematuria Risk Stratification Guide.&#x000a0;Evidence suggests that the majority of patients with true microhematuria are not appropriately referred to urology, which could lead to delayed diagnosis of malignancy.<xref ref-type="bibr" rid="article-22710.r10">[10]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-22710.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Genitourinary disorders primarily cause hematuria, although systemic diseases can manifest with blood in the urine. The etiology of hematuria&#x000a0;is divided into glomerular or nonglomerular hematuria for classification, although the cause in many cases may be idiopathic or undetermined. In general, glomerular sources are often associated with proteinuria.</p>
        <p>In infants and young children, hematuria may signal Wilms tumor,&#x000a0;polycystic kidney disease, Alport syndrome, inherited nephritis, glomerulonephritis, hypercalciuria, urinary tract infections, and, in the Black population, sickle cell disease.&#x000a0;In older individuals, the most common causes are urinary tract infections, various urological malignancies (eg, kidney and bladder cancers), urolithiasis, postinfectious and other types of glomerulonephritis, trauma, prostatic enlargement, and urinary instrumentation.&#x000a0;In about 50% of cases, a specific cause of the hematuria can be identified, meaning no definite etiology can be determined about half the time.&#x000a0;When hematuria presents with proteinuria, casts, or dysmorphic (ie, malformed) RBCs, this usually signals glomerular pathology with at least moderate kidney disease.&#x000a0;Some common glomerular causes of hematuria include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Alport syndrome</p>
          </list-item>
          <list-item>
            <p>Crescentic glomerulonephritis</p>
          </list-item>
          <list-item>
            <p>Diffuse progressive glomerulonephritis</p>
          </list-item>
          <list-item>
            <p>Focal segmental glomerulonephritis</p>
          </list-item>
          <list-item>
            <p>Goodpasture syndrome</p>
          </list-item>
          <list-item>
            <p>IgA vasculitis (Hen&#x000f6;ch-Schonlein purpura)</p>
          </list-item>
          <list-item>
            <p>Hypercalciuria</p>
          </list-item>
          <list-item>
            <p>IgA nephropathy</p>
          </list-item>
          <list-item>
            <p>Lupus nephritis</p>
          </list-item>
          <list-item>
            <p>Membranous glomerulonephritis</p>
          </list-item>
          <list-item>
            <p>Minimal change disease</p>
          </list-item>
          <list-item>
            <p>Nephrotic syndrome</p>
          </list-item>
          <list-item>
            <p>Rapidly progressive (pauci-immune) glomerulonephritis</p>
          </list-item>
          <list-item>
            <p>Polycystic kidney disease</p>
          </list-item>
          <list-item>
            <p>Post-streptococcal (post-infectious) glomerulonephritis</p>
          </list-item>
          <list-item>
            <p>Thin basement membrane disease (formerly benign familial hematuria)</p>
          </list-item>
        </list>
        <p>Nonglomerular causes typically demonstrate normal RBCs on microscopic urinalysis without proteinuria or casts. Common nonglomerular causes of hematuria include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Bladder calculi</p>
          </list-item>
          <list-item>
            <p>Benign prostatic hyperplasia</p>
          </list-item>
          <list-item>
            <p>Endometriosis of the urinary tract</p>
          </list-item>
          <list-item>
            <p>Strenuous exercise</p>
          </list-item>
          <list-item>
            <p>Foreign bodies in the urinary tract (eg, stones, catheters, and stents)</p>
          </list-item>
          <list-item>
            <p>Genitourinary mucosal injury by instrumentation, including biopsies</p>
          </list-item>
          <list-item>
            <p>Hematological disorders like sickle cell anemia, thrombocytopenia, and coagulopathies</p>
          </list-item>
          <list-item>
            <p>Hemorrhagic cystitis</p>
          </list-item>
          <list-item>
            <p>Infections (eg, cystitis, urethritis, and prostatitis)</p>
          </list-item>
          <list-item>
            <p>Malignancy (eg, renal cell carcinoma, bladder, and prostate cancer)</p>
          </list-item>
          <list-item>
            <p>Medication-related (eg, cyclophosphamide)</p>
          </list-item>
          <list-item>
            <p>Nephrolithiasis, urolithiasis</p>
          </list-item>
          <list-item>
            <p>Nutcracker Syndrome</p>
          </list-item>
          <list-item>
            <p>Radiation cystitis</p>
          </list-item>
          <list-item>
            <p>Schistosomiasis (Africa and endemic regions)</p>
          </list-item>
          <list-item>
            <p>Trauma involving the genitourinary tract</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-22710.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Gross hematuria is a common presentation in outpatient clinics and emergency departments. Asymptomatic hematuria is thought to be much more prevalent than symptomatic hematuria and may be present for years before it is discovered.<xref ref-type="bibr" rid="article-22710.r11">[11]</xref><xref ref-type="bibr" rid="article-22710.r12">[12]</xref>&#x000a0;The evaluation of hematuria, especially microhematuria, is often delayed in women, which can cause poorer outcomes for bladder and other urological cancers in females.<xref ref-type="bibr" rid="article-22710.r5">[5]</xref></p>
        <p>The prevalence of hematuria varies widely according to the definition used and the availability of medical evaluation. In the United States (US), the prevalence of microscopic hematuria is estimated at 6.5% of the population.<xref ref-type="bibr" rid="article-22710.r3">[3]</xref>&#x000a0;The prevalence varies worldwide, depending on the population studied and the definition used.<xref ref-type="bibr" rid="article-22710.r1">[1]</xref><xref ref-type="bibr" rid="article-22710.r3">[3]</xref>&#x000a0;One study in Japan, where annual health check-ups with urine dipstick are the standard of care, found that 5% to 10% of the population were dipstick-positive for hematuria.<xref ref-type="bibr" rid="article-22710.r13">[13]</xref>&#x000a0;Another meta-analysis showed that the prevalence of asymptomatic microhematuria varies from 0.19% to 16%. Prevalence depends greatly on the ages and population studies. Older men have an especially high prevalence of asymptomatic microhematuria, with some estimates as high as 21%.<xref ref-type="bibr" rid="article-22710.r14">[14]</xref></p>
        <p>A primary focus of an evaluation of hematuria is to identify and exclude any underlying malignancy; hematuria is the presenting symptom in most bladder cancers.&#x000a0;The overall incidence of discovering a genitourinary malignancy in patients with microscopic hematuria is approximately 3%.<xref ref-type="bibr" rid="article-22710.r3">[3]</xref><xref ref-type="bibr" rid="article-22710.r5">[5]</xref><xref ref-type="bibr" rid="article-22710.r15">[15]</xref>&#x000a0;With gross hematuria, the incidence rises to 10% to 20%.<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/Keywords/UserViewPopup/161028#link_31930164">[36]</ext-link> This risk is increased in some groups and is related to gender, age, smoking history, some chemical exposures (eg, benzene and aromatic amines), and degree of hematuria.<xref ref-type="bibr" rid="article-22710.r16">[16]</xref><xref ref-type="bibr" rid="article-22710.r17">[17]</xref>&#x000a0;The American Cancer Society estimates that there will be about 82,290 new cases of bladder cancer, approximately 62,420 in men and 19,870 in women, in 2023, with 16,710 deaths.&#x000a0;The National Cancer Institute has estimated the annual incidence of bladder cancer at 18.7 per 100,000 population. However, the overall incidence is slowly decreasing.&#x000a0;For renal cancer, the estimated yearly incidence in the US is around 79,000, about 50,000 men and 29,000 women, with 14,000 mortalities.&#x000a0;Worldwide, over 400,000 persons are estimated to be diagnosed with this disease yearly, with about 180,000 deaths annually. The overall incidence appears to be slowly increasing.&#x000a0;</p>
        <p>The overall incidence of glomerulonephritis has been reported as high as 134 per 100,000 patient years, but reliable worldwide statistics are difficult to obtain.<xref ref-type="bibr" rid="article-22710.r18">[18]</xref>&#x000a0;Nephrolithiasis rates vary with gender, being about twice as common in males as females, ethnicity, and geographic region. The reported incidence of urolithiasis ranges from 7% to 13% in the US and Canada, 5% to 9% in Europe, and 1% to 5% in Asia.<xref ref-type="bibr" rid="article-22710.r19">[19]</xref>&#x000a0;UTIs have an overall estimated global prevalence of 0.7%.&#x000a0;The main risk factors for UTI are increasing age, previous history of UTI, sexual activity, and diabetes.<xref ref-type="bibr" rid="article-22710.r20">[20]</xref>&#x000a0;Acute cystitis is far more common than pyelonephritis; for every pyelonephritis case, there are 18 to 28 cases of acute cystitis.<xref ref-type="bibr" rid="article-22710.r21">[21]</xref>&#x000a0;Of note, while UTI is a common cause of microhematuria, the resolution of microhematuria after UTI treatment should be documented, as malignancy and UTI may coexist.<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/Keywords/UserViewPopup/161028#link_31930164">[36]</ext-link>&#x000a0;</p>
        <p>Benign prostatic hyperplasia (BPH) is extremely common, but most affected individuals initially demonstrate urinary symptoms other than hematuria. Half of the men older than 50 demonstrate some evidence of BPH.<xref ref-type="bibr" rid="article-22710.r22">[22]</xref><xref ref-type="bibr" rid="article-22710.r23">[23]</xref>&#x000a0;This increases with age by about 2% to 2.5% yearly.<xref ref-type="bibr" rid="article-22710.r24">[24]</xref>&#x000a0;In the US, the incidence of BPH in men aged 60 to 69 years is 70%, which rises to over 80% in men older than 70 years.<xref ref-type="bibr" rid="article-22710.r25">[25]</xref>&#x000a0;Polycystic kidney disease affects an estimated 4 to 7 million individuals worldwide and accounts for up to 15% of patients with end-stage kidney disease.<xref ref-type="bibr" rid="article-22710.r26">[26]</xref>&#x000a0;Approximately 5% of all traumas involve the kidney. The majority of such traumas come from motor vehicle accidents, followed by sports injuries and falls.<xref ref-type="bibr" rid="article-22710.r27">[27]</xref><xref ref-type="bibr" rid="article-22710.r28">[28]</xref></p>
        <p>Nutcracker syndrome, also known as left renal vein obstruction or entrapment, is a rare, sometimes symptomatic syndrome where the flow of the left renal vein into the inferior vena cava is blocked, often by the superior mesenteric artery.<xref ref-type="bibr" rid="article-22710.r29">[29]</xref> The incidence of this entity is unknown but is most common in adults in the second and third decades. See the StatPearls companion article "Nutcracker Syndrome" for additional information.<xref ref-type="bibr" rid="article-22710.r30">[30]</xref>&#x000a0;Asymptomatic hematuria can be found in 4% of normal school-aged children, more often in girls than boys.<xref ref-type="bibr" rid="article-22710.r31">[31]</xref></p>
        <p>Inherited illnesses that cause hematuria are relatively uncommon.&#x000a0;Alport syndrome is more common in the US, where the incidence is estimated at 1 in 5,000 population or up to 60,000 total affected individuals.&#x000a0;The incidence in Europe is lower, estimated at 1 in 50,000.<xref ref-type="bibr" rid="article-22710.r32">[32]</xref>&#x000a0;Approximately 3% of all children in the US with end-stage renal failure have Alport syndrome.&#x000a0;Autosomal dominant polycystic kidney disease is found in roughly 1 in every 1,000 live births.&#x000a0;The incidence of Goodpasture syndrome is fewer than 2 cases per 1 million population.<xref ref-type="bibr" rid="article-22710.r33">[33]</xref>&#x000a0;Thin basement membrane disease, formerly known as benign familial hematuria, affects at least 1% of the population worldwide. Some patients previously thought to have thin basement membrane disease were found to have variations of Alport Syndrome.<xref ref-type="bibr" rid="article-22710.r32">[32]</xref>&#x000a0;Additionally, sickle cell disease affects about 100,000 Black Americans, or 1 out of every 365 Black Americans, according to the Centers for Disease Control and Prevention.<xref ref-type="bibr" rid="article-22710.r34">[34]</xref><xref ref-type="bibr" rid="article-22710.r35">[35]</xref>&#x000a0;This can cause renal papillary necrosis or other renal infarctions, resulting in microscopic hematuria.<xref ref-type="bibr" rid="article-22710.r36">[36]</xref>&#x000a0;Sickle cell trait is found in 1 out of every 12 babies of African ancestry born in the US.</p>
        <p>Furthermore, medications can cause hematuria or urinary discoloration due to pseudohematuria (ie, red, pink, or brown urine discoloration), kidney damage, nephrolithiasis or urolithiasis, or hemorrhagic cystitis.&#x000a0;Medications that can lead to hematuria include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Allopurinol</p>
          </list-item>
          <list-item>
            <p>Blood thinners, such as warfarin or antiplatelet drugs</p>
          </list-item>
          <list-item>
            <p>Captopril</p>
          </list-item>
          <list-item>
            <p>Cephalosporins</p>
          </list-item>
          <list-item>
            <p>Chlorpromazine&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Cyclophosphamide</p>
          </list-item>
          <list-item>
            <p>Dichlorphenamide&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Furosemide</p>
          </list-item>
          <list-item>
            <p>Hydralazine</p>
          </list-item>
          <list-item>
            <p>Indinavir</p>
          </list-item>
          <list-item>
            <p>Ifosfamide</p>
          </list-item>
          <list-item>
            <p>Metronidazole</p>
          </list-item>
          <list-item>
            <p>Nitrofurantoin</p>
          </list-item>
          <list-item>
            <p>Phenazopyridine</p>
          </list-item>
          <list-item>
            <p>Phenolphthalein</p>
          </list-item>
          <list-item>
            <p>Minocycline</p>
          </list-item>
          <list-item>
            <p>Mirtazapine&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Penicillin</p>
          </list-item>
          <list-item>
            <p>Propylthiouracil</p>
          </list-item>
          <list-item>
            <p>Rifampin</p>
          </list-item>
          <list-item>
            <p>Senna</p>
          </list-item>
          <list-item>
            <p>Sulfa drugs</p>
          </list-item>
          <list-item>
            <p>Thioridazine</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-22710.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Hematuria may result from structural alterations due to an injury, infection, or a mass anywhere in the genitourinary tract.&#x000a0;Anticoagulation alone does not cause hematuria but may exacerbate this symptom.&#x000a0;Patients on anticoagulants or antiplatelet therapy should receive the same evaluation as individuals not on such agents, as their risk of malignancy is the same.<xref ref-type="bibr" rid="article-22710.r1">[1]</xref><xref ref-type="bibr" rid="article-22710.r37">[37]</xref><xref ref-type="bibr" rid="article-22710.r38">[38]</xref><xref ref-type="bibr" rid="article-22710.r39">[39]</xref><xref ref-type="bibr" rid="article-22710.r40">[40]</xref>&#x000a0;Immunological or inflammatory processes may damage the integrity of the renal glomerular basement membrane, mesangium, or microvascular endothelium.<xref ref-type="bibr" rid="article-22710.r41">[41]</xref>&#x000a0;This usually presents as glomerular bleeding.</p>
        <p>Nonglomerular causes of bleeding, including nephrolithiasis, urolithiasis, certain drugs, nephrocalcinosis,&#x000a0;genitourinary neoplasms, trauma-related urothelial mucosal damage, catheterization, urological biopsies or similar procedures, benign prostatic hyperplasia, radiation exposure, and various chemicals may cause erosion or otherwise damage the urothelial surface somewhere in the urinary tract, leading to hematuria.</p>
      </sec>
      <sec id="article-22710.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>There are many ways to classify hematuria, but the most clinically useful division is gross and microscopic.</p>
        <p>
<bold>Gross Hematuria</bold>
</p>
        <p>Gross hematuria is visible blood in the urine.&#x000a0;Gross hematuria may be reddish or pink due to lower tract abnormalities. It can also present as brown or tea-colored urine due to oxidation of urinary heme pigments. Gross hematuria may be associated with significant urological disease whether or not symptoms are present. A patient's history may provide sufficient explanation to explain the hematuria, such as recent urological surgery or instrumentation, a urinary tract infection, or passage of a kidney stone.&#x000a0;If unexplained, gross hematuria generally requires further workup, including imaging and cystoscopy, to eliminate urological malignancies, particularly those older than 35. Furthermore, clinicians should be aware that the presence of gross hematuria automatically makes the case high-risk.</p>
        <p>
<bold>Microscopic Hematuria</bold>
</p>
        <p>Microscopic hematuria may be further classified into the following subtypes:</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Asymptomatic</bold>: This may be associated with bladder and other urological cancers. Typically, normal RBCs are seen microscopically. Requires further risk-stratified workup.</p>
          </list-item>
          <list-item>
            <p><bold>Asymptomatic with proteinuria</bold>: Proteinuria in asymptomatic patients is suggestive of glomerulonephritis. Dysmorphic, atypical RBCs are frequently seen with microscopic exams. A workup for glomerular disorders should be performed and may require a renal biopsy.</p>
          </list-item>
          <list-item>
            <p><bold>Symptomatic</bold>: This subtype is associated with urinary symptoms and is often suggestive of infection, prostatitis, BPH, or other urinary disorders. Further investigation should be performed with follow-up as warranted.</p>
          </list-item>
        </list>
        <p>
<bold>Clinical Symptoms of Hematuria</bold>
</p>
        <p>A thorough history and focused physical examination can lead to proper evaluation, improved diagnosis, and optimal management. When obtaining a clinical history, other symptoms associated with hematuria may be noted, including:</p>
        <list list-type="bullet">
          <list-item>
            <p>Active menstruation</p>
          </list-item>
          <list-item>
            <p>Back or flank pain&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Constitutional symptoms like weight loss, anorexia, cachexia</p>
          </list-item>
          <list-item>
            <p>Fever (unexplained)</p>
          </list-item>
          <list-item>
            <p>Flank mass</p>
          </list-item>
          <list-item>
            <p>Hearing loss</p>
          </list-item>
          <list-item>
            <p>Hemoptysis&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Joint pains, oral ulcers, rash</p>
          </list-item>
          <list-item>
            <p>Leg swelling</p>
          </list-item>
          <list-item>
            <p>Lower abdominal pain</p>
          </list-item>
          <list-item>
            <p>Passing urinary calculi</p>
          </list-item>
          <list-item>
            <p>Recent throat or skin infection</p>
          </list-item>
          <list-item>
            <p>Voiding and urinary symptoms such as:
<list list-type="bullet"><list-item><p>Dysuria</p></list-item><list-item><p>Frequency</p></list-item><list-item><p>Hesitancy</p></list-item><list-item><p>Incomplete emptying</p></list-item><list-item><p>Intermittent stream</p></list-item><list-item><p>Urgency</p></list-item><list-item><p>Weak urinary stream</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>Female patients during menstruation or with vaginal bleeding should either have a catheterized urine sample, use a tampon with cleaning of any residual blood before voiding, or be reevaluated when the gynecologic bleeding has resolved.<xref ref-type="bibr" rid="article-22710.r1">[1]</xref>&#x000a0;After a UTI, at least 4 to 6 weeks should elapse before a repeat urinalysis for hematuria.&#x000a0;Patients should be asked about previous such episodes and any family history of hematuria. A detailed medical history, including any recent surgical procedures or biopsies, is essential for a proper evaluation.&#x000a0;Medications should be carefully reviewed, particularly about any blood thinners. Certain medications can cause false positive dipstick readings, such as peroxidases from organic sources, semen, metronidazole, and sodium hypochlorite.<xref ref-type="bibr" rid="article-22710.r5">[5]</xref><xref ref-type="bibr" rid="article-22710.r42">[42]</xref>&#x000a0;False-negative dipstick results are possible from extremely high urinary ascorbic acid levels.<xref ref-type="bibr" rid="article-22710.r5">[5]</xref>&#x000a0;Clinicians should also ascertain the patient's smoking history as 10 pack-years or more is a significant risk factor for urothelial malignancies such as bladder cancer. The risk is higher as the smoking history increases.&#x000a0;Even after a negative full evaluation, persistent or recurrent microhematuria is reclassified as either "Intermediate" or "High-Risk."<xref ref-type="bibr" rid="article-22710.r1">[1]</xref><xref ref-type="bibr" rid="article-22710.r43">[43]</xref></p>
        <p>
<bold>High-Risk Factors for Urothelial Cancers&#x000a0;</bold>
</p>
        <p>Clinical factors that are associated with a high risk for urothelial cancer include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Degree and persistence of microhematuria</p>
          </list-item>
          <list-item>
            <p>Family history of Lynch syndrome or urothelial malignancies</p>
          </list-item>
          <list-item>
            <p>History of pelvic radiation therapy</p>
          </list-item>
          <list-item>
            <p>History of unexplained gross hematuria</p>
          </list-item>
          <list-item>
            <p>Increasing age (especially older than 60 years)</p>
          </list-item>
          <list-item>
            <p>Indwelling catheters, suprapubic tubes</p>
          </list-item>
          <list-item>
            <p>Irritative lower urinary tract symptoms</p>
          </list-item>
          <list-item>
            <p>Male gender</p>
          </list-item>
          <list-item>
            <p>Occupational exposure to benzene, aromatic amines, and similar chemicals</p>
          </list-item>
          <list-item>
            <p>Prior chemotherapy drug exposure (cyclophosphamide, ifosfamide)</p>
          </list-item>
          <list-item>
            <p>Significant smoking history&#x000a0;<xref ref-type="bibr" rid="article-22710.r1">[1]</xref><xref ref-type="bibr" rid="article-22710.r2">[2]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Physical Exam Findings</bold>
</p>
        <p>A complete physical examination can contribute to making a valid differential diagnosis. Important signs to look for when assessing patients with hematuria include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Costovertebral angle tenderness</p>
          </list-item>
          <list-item>
            <p>Edema of the lower extremities</p>
          </list-item>
          <list-item>
            <p>Fever</p>
          </list-item>
          <list-item>
            <p>Flank mass or tenderness</p>
          </list-item>
          <list-item>
            <p>Gynecological abnormalities</p>
          </list-item>
          <list-item>
            <p>Hearing impairments</p>
          </list-item>
          <list-item>
            <p>Hypertension</p>
          </list-item>
          <list-item>
            <p>Joint swelling</p>
          </list-item>
          <list-item>
            <p>Lymphadenopathy</p>
          </list-item>
          <list-item>
            <p>Meatal blood, caruncles, or other abnormalities</p>
          </list-item>
          <list-item>
            <p>Palpable, enlarged, cystic kidneys</p>
          </list-item>
          <list-item>
            <p>Periorbital edema</p>
          </list-item>
          <list-item>
            <p>Presence of pallor, icterus, oral ulcers, or rashes</p>
          </list-item>
          <list-item>
            <p>Pubic or suprapubic tenderness</p>
          </list-item>
          <list-item>
            <p>Urethral or vaginal discharge, injury, or tear</p>
          </list-item>
          <list-item>
            <p>Vaginal bleeding&#x000a0;<xref ref-type="bibr" rid="article-22710.r1">[1]</xref><xref ref-type="bibr" rid="article-22710.r2">[2]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-22710.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Evaluation of hematuria is often deficient, inadequate, or incomplete.<xref ref-type="bibr" rid="article-22710.r1">[1]</xref>&#x000a0;More than half or more of the patients identified as having hematuria in primary care practices are not properly worked up or referred to urology promptly.<xref ref-type="bibr" rid="article-22710.r44">[44]</xref>&#x000a0;Cystoscopy is underutilized overall, as there is a tendency to rely excessively&#x000a0;on diagnostic imaging alone.<xref ref-type="bibr" rid="article-22710.r1">[1]</xref><xref ref-type="bibr" rid="article-22710.r5">[5]</xref>&#x000a0;This is particularly disturbing as most of the hematuria caused by cancers are from bladder neoplasms that are optimally diagnosed almost exclusively by cystoscopy.<xref ref-type="bibr" rid="article-22710.r1">[1]</xref><xref ref-type="bibr" rid="article-22710.r45">[45]</xref><xref ref-type="bibr" rid="article-22710.r46">[46]</xref><xref ref-type="bibr" rid="article-22710.r47">[47]</xref><xref ref-type="bibr" rid="article-22710.r48">[48]</xref>&#x000a0;Primary care practitioners frequently order renal ultrasonography, where more detailed and accurate imaging (eg, computed tomography urogram) is generally required.<xref ref-type="bibr" rid="article-22710.r1">[1]</xref><xref ref-type="bibr" rid="article-22710.r49">[49]</xref>&#x000a0;In most studies, the proper use of appropriate urological imaging and cystoscopy occurs in fewer than 20% of patients with hematuria, with some variation based on gender and race.<xref ref-type="bibr" rid="article-22710.r1">[1]</xref><xref ref-type="bibr" rid="article-22710.r45">[45]</xref><xref ref-type="bibr" rid="article-22710.r46">[46]</xref><xref ref-type="bibr" rid="article-22710.r47">[47]</xref>&#x000a0;The evaluation of hematuria, especially microhematuria, is often delayed in women, where it is often assumed to be caused by a urinary tract infection, menstrual flow contamination, or vaginal bleeding. This can cause poorer outcomes for bladder and other urological cancers in females.<xref ref-type="bibr" rid="article-22710.r5">[5]</xref>&#x000a0;</p>
        <p>
<bold>Urinalysis</bold>
</p>
        <p>Urinalysis is the initial and most useful test to detect hematuria. Although urine dipsticks are widely available and can be performed quickly, they can give false-positive or false-negative results and require microscopic analysis to confirm positive findings. The presence of 3 or more RBCs per high power field on microscopic examination of the urine sediment establishes the diagnosis, although there is no "safe" lower limit of hematuria.<xref ref-type="bibr" rid="article-22710.r1">[1]</xref><xref ref-type="bibr" rid="article-22710.r2">[2]</xref>&#x000a0;The finding of an abnormal urine appearance or urine pH, proteinuria, white blood cells, nitrites, leukocyte esterase, bacteria, crystals, or casts outside of the reference range helps identify the source of the hematuria.&#x000a0;</p>
        <p><bold>Nonglomerular Hematuria</bold>&#x000a0;<bold>Evaluation</bold></p>
        <p>Nongomerular hematuria is the finding of normal red blood cells without apparent cause, including no evidence of infection, renal failure, or glomerular disease. The absence of an identifiable cause suggests possible benign prostatic hyperplasia (BPH), urolithiasis, or a urinary tract malignancy and warrants further evaluation based primarily on the overall stratified urological cancer risk as outlined below.<xref ref-type="bibr" rid="article-22710.r1">[1]</xref>&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Urinary tract infection</bold>: Infection is suspected as the source of the hematuria if the urinalysis shows a urine specimen with significant white blood cells, positive nitrites, and leukocyte esterase, together with urinary symptoms of frequency, urgency, or dysuria.<xref ref-type="bibr" rid="article-22710.r50">[50]</xref> A urine culture should be done, and the infection should be treated appropriately.<xref ref-type="bibr" rid="article-22710.r51">[51]</xref> After treating the infection and eliminating any abnormal urinary symptoms, a repeat urinalysis should be performed to verify that the hematuria has resolved. If the hematuria persists, a risk-stratified approach to management should be adopted.<xref ref-type="bibr" rid="article-22710.r1">[1]</xref>&#x000a0;See StatPearls companion article on "Acute Cystitis" for additional information on acute cystitis management.<xref ref-type="bibr" rid="article-22710.r52">[52]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Bladder, ureteral, and renal malignancies</bold>: Cancers&#x000a0;are the most potentially troubling etiologies of painless hematuria, especially if the blood is easily visible. A full diagnostic urological evaluation is primarily designed to detect such cancers, not necessarily to identify the source of the hematuria. See StatPearls companion articles on "Renal Cancer" and "Bladder Cancer" for additional information on evaluating these conditions.<xref ref-type="bibr" rid="article-22710.r53">[53]</xref><xref ref-type="bibr" rid="article-22710.r54">[54]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Nephrolithiasis</bold>: Renal calculi are&#x000a0;a common cause of hematuria. The urinalysis will often show crystals, but this alone is not diagnostic. Some patients may be asymptomatic, but others will have a history of chronic infection or develop symptoms of acute renal colic with severe abdominal or flank pain, nausea, and vomiting. Imaging studies, including a renal ultrasound with a kidney, ureter, bladder x-ray, or a computed tomography scan of the abdomen, are required for proper diagnosis and to demonstrate the urinary calculi.<xref ref-type="bibr" rid="article-22710.r55">[55]</xref><xref ref-type="bibr" rid="article-22710.r56">[56]</xref><xref ref-type="bibr" rid="article-22710.r57">[57]</xref>&#x000a0;See our companion StatPearls articles on "Nephrolithiasis" and&#x000a0;"Urolithiasis."&#x000a0;<xref ref-type="bibr" rid="article-22710.r55">[55]</xref><xref ref-type="bibr" rid="article-22710.r57">[57]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Prostatic bleeding</bold>: In older male patients with known or suspected BPH, hematuria due to a prostatic etiology should be suspected.<xref ref-type="bibr" rid="article-22710.r58">[58]</xref>&#x000a0;Unfortunately, there is no way to reliably determine this without completing a full workup, which generally consists of appropriate genitourinary imaging and a cystoscopy.<xref ref-type="bibr" rid="article-22710.r1">[1]</xref> See StatPearls companion article on "Benign Prostatic Hyperplasia" for additional information.<xref ref-type="bibr" rid="article-22710.r58">[58]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Traumatic urinary bleeding</bold>: Traumatic bleeding&#x000a0;can be minimal or severe and potentially life-threatening, which is why evaluating hematuria in a trauma setting requires a more urgent approach. Unstable patients may require immediate surgical exploration without even diagnostic imaging first. Renal trauma should be suspected in any abdominal trauma case, particularly falls and motor vehicle accidents.<xref ref-type="bibr" rid="article-22710.r27">[27]</xref>&#x000a0;A possible urological injury should be suspected in all pelvic trauma cases until proven otherwise by appropriate imaging.<xref ref-type="bibr" rid="article-22710.r59">[59]</xref><xref ref-type="bibr" rid="article-22710.r60">[60]</xref>&#x000a0;Blood at the urethral meatus or an inability to void is suggestive of a urethral or bladder injury, which should ideally be evaluated by retrograde urethrography before attempting Foley catheterization.<xref ref-type="bibr" rid="article-22710.r59">[59]</xref><xref ref-type="bibr" rid="article-22710.r60">[60]</xref> A cystogram with adequate bladder filling, typically at least 300 mL, will demonstrate any extravasation or abnormal leakage.<xref ref-type="bibr" rid="article-22710.r59">[59]</xref><xref ref-type="bibr" rid="article-22710.r60">[60]</xref> Potential renal trauma requires immediate computed tomography (CT) imaging, if possible.<xref ref-type="bibr" rid="article-22710.r27">[27]</xref><xref ref-type="bibr" rid="article-22710.r59">[59]</xref><xref ref-type="bibr" rid="article-22710.r60">[60]</xref>&#x000a0;See StatPearls companion articles on "Kidney Trauma" and "Lower Genitourinary Trauma."&#x000a0;<xref ref-type="bibr" rid="article-22710.r27">[27]</xref><xref ref-type="bibr" rid="article-22710.r60">[60]</xref></p>
          </list-item>
        </list>
        <p>The standard evaluation for hematuria traditionally comprises urine cytology, upper tract imaging with an intravenous pyelogram, now considered obsolete, a CT urogram consisting of a CT of the abdomen and pelvis with and without IV contrast, and a cystoscopy. Cystoscopy is 98% sensitive in detecting bladder cancer.<xref ref-type="bibr" rid="article-22710.r61">[61]</xref>&#x000a0;Urine cytology and similar biomarkers are not currently recommended in the initial workup for hematuria as they have not demonstrated any substantial value and do not eliminate the need for a cystoscopy.<xref ref-type="bibr" rid="article-22710.r1">[1]</xref>&#x000a0;However, the occasional patient with carcinoma-in-situ of the bladder may have a negative cystoscopy and would only be detected by suspicious cytology.<xref ref-type="bibr" rid="article-22710.r62">[62]</xref>&#x000a0;Other biomarkers, such as fluorescence-in-situ-hybridization (FISH) assays, are cumbersome and expensive to use but may help in borderline or equivocal cases, determining response to Bacillus Calmette-Gu&#x000e9;rin (BCG) therapy and identifying urothelial cancer of the upper tracts that may be poorly visualized on imaging.<xref ref-type="bibr" rid="article-22710.r63">[63]</xref> Therefore, there is a role for cytology and possibly other biomarkers like FISH assays in patients with persistent microhematuria who also have other high-risk factors for possible carcinoma-in-situ, such as unexplained irritative urinary symptoms, persistent microhematuria, or patients with a significant smoking history.<xref ref-type="bibr" rid="article-22710.r1">[1]</xref><xref ref-type="bibr" rid="article-22710.r62">[62]</xref></p>
        <p>
<bold>The 2020 American Urological Association Guideline on Microhematuria Risk Stratification Guide&#x000a0;</bold>
</p>
        <p>The current guideline recommendations for evaluating hematuria rely on a risk-stratification approach to avoid expensive, unnecessary, low-yield, and uncomfortable testing in lower-risk individuals.<xref ref-type="bibr" rid="article-22710.r1">[1]</xref><xref ref-type="bibr" rid="article-22710.r64">[64]</xref><xref ref-type="bibr" rid="article-22710.r17">[17]</xref><xref ref-type="bibr" rid="article-22710.r65">[65]</xref><xref ref-type="bibr" rid="article-22710.r64">[64]</xref></p>
        <p><bold>Low-risk</bold>&#x000a0;<bold>patients</bold></p>
        <p>To be classified as low-risk, patients must meet the following criteria:</p>
        <list list-type="bullet">
          <list-item>
            <p>Women younger than 50 years</p>
          </list-item>
          <list-item>
            <p>Men younger than 40 years</p>
          </list-item>
          <list-item>
            <p>Non-smoker or &#x0003c;10 pack-years</p>
          </list-item>
          <list-item>
            <p>Number of RBC/HPF of 4 to 10</p>
          </list-item>
          <list-item>
            <p>No prior episodes of microhematuria</p>
          </list-item>
          <list-item>
            <p>Estimated cancer risk of &#x0003c;1%</p>
          </list-item>
        </list>
        <p>Either of the following approaches may be used for the evaluation of low-risk patients, which should be selected through a shared decision-making process:</p>
        <list list-type="bullet">
          <list-item>
            <p>Repeat urinalysis within 6 months
<list list-type="bullet"><list-item><p>If negative: Repeat after 6 more months.</p></list-item><list-item><p>Negative repeat urinalysis: No further workup is needed; resume routine surveillance.</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Renal ultrasound and cystoscopy
<list list-type="bullet"><list-item><p>Positive findings: Treat accordingly</p></list-item><list-item><p>Negative findings: Repeat urinalysis within 12 months</p></list-item><list-item><p>Negative findings with persistent hematuria: Consider CT urogram or bilateral retrograde pyelograms</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<bold>Intermediate-risk patients</bold>
</p>
        <p>To be classified as intermediate-risk, patients must meet the following criteria:</p>
        <list list-type="bullet">
          <list-item>
            <p>Women aged 50 to 59 years</p>
          </list-item>
          <list-item>
            <p>Men aged 40 to 59 years</p>
          </list-item>
          <list-item>
            <p>Smoker for 10 to 30 pack-years</p>
          </list-item>
          <list-item>
            <p>Number of RBCs/HPF of 11 to 25</p>
          </list-item>
          <list-item>
            <p>One or more high-risk factors&#x000a0;(Refer to "<bold>High-Risk Factors for Urothelial Cancers</bold>"&#x000a0;in the <bold>History and Physical</bold>&#x000a0;section for more information)</p>
          </list-item>
          <list-item>
            <p>Does not meet criteria for high-risk patient classification&#x000a0;</p>
          </list-item>
          <list-item>
            <p>A previous episode of low-risk hematuria without further evaluation</p>
          </list-item>
          <list-item>
            <p>Estimated cancer risk of 1% to 2%</p>
          </list-item>
        </list>
        <p>In intermediate-risk patients, evaluation with a renal ultrasound and cystoscopy should be performed. Based on the results, the following diagnostic studies are recommended:&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Positive Findings: Treat accordingly</p>
          </list-item>
          <list-item>
            <p>Negative Findings: Repeat urinalysis within 12 months</p>
          </list-item>
          <list-item>
            <p>Negative Findings with persistent hematuria: Consider CT urogram or bilateral retrograde pyelograms</p>
          </list-item>
        </list>
        <p>
<bold>High-Risk&#x000a0;patients</bold>
</p>
        <p>To be classified as high-risk, patients must meet the following criteria:</p>
        <list list-type="bullet">
          <list-item>
            <p>Women and men aged 60 years or older</p>
          </list-item>
          <list-item>
            <p>Smoker: More than 30 pack-years</p>
          </list-item>
          <list-item>
            <p>More than 25 RBCs per HPF</p>
          </list-item>
          <list-item>
            <p>History of gross hematuria</p>
          </list-item>
          <list-item>
            <p>Prior episodes of hematuria not previously evaluated by cystoscopy or imaging</p>
          </list-item>
          <list-item>
            <p>Estimated cancer risk &#x02265;10%</p>
          </list-item>
        </list>
        <p>In high-risk patients, evaluation should be performed with a CT abdomen and pelvis without and with IV contrast (ie, CT urogram) and cystoscopy. Based on the results, the following diagnostic studies are recommended:&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Positive findings: Treat accordingly</p>
          </list-item>
          <list-item>
            <p>Negative findings: Repeat urinalysis within 12 months. If urine remains negative, resume routine surveillance.</p>
          </list-item>
          <list-item>
            <p>Negative Findings&#x000a0;with persistent hematuria:
<list list-type="bullet"><list-item><p>Consider an evaluation for glomerular bleeding</p></list-item><list-item><p>Based on shared decision-making, determine whether to continue observation or repeat the evaluation with cystoscopy and CT urogram.</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>MRI urography may be substituted if a CT urogram cannot be performed. If neither is possible, a noncontrast CT scan, ultrasound of the abdomen and pelvis, and bilateral retrograde pyelogram may be utilized.<xref ref-type="bibr" rid="article-22710.r1">[1]</xref>&#x000a0;Upper tract imaging should be done regardless of risk category in patients with hematuria and a family history of renal cell carcinoma or any genetic predisposition to renal malignancies.<xref ref-type="bibr" rid="article-22710.r1">[1]</xref>&#x000a0;Initial imaging during pregnancy should be limited to ultrasonography.&#x000a0;Blue light cystoscopy and other enhanced visualization techniques may be useful in patients previously diagnosed with bladder cancer, but their role in evaluating patients with microscopic hematuria has not yet been fully established.<xref ref-type="bibr" rid="article-22710.r1">[1]</xref></p>
        <p>Patients with microscopic hematuria whose initial evaluations are negative have been found to have an ultimate urologic malignancy rate of &#x0003c;1% and, therefore, do not generally require follow-up urological evaluations unless they develop gross hematuria.<xref ref-type="bibr" rid="article-22710.r66">[66]</xref>&#x000a0;Nevertheless, a follow-up urinalysis in 12 months is recommended by the guidelines.<xref ref-type="bibr" rid="article-22710.r1">[1]</xref>&#x000a0;The patient's primary care physician can perform this. Patients with persistent microscopic hematuria have a higher risk of malignancy than those who test negative on follow-up examinations and, therefore, should be reclassified as intermediate- or high-risk.<xref ref-type="bibr" rid="article-22710.r1">[1]</xref><xref ref-type="bibr" rid="article-22710.r43">[43]</xref></p>
        <p>
<bold>Cytology and Urinary Biomarkers</bold>
</p>
        <p>Various biomarkers and cytology are not recommended for the initial evaluation of patients with microscopic hematuria due to their high false negative rate and lack of proven benefit in sufficient, large, prospective randomized trials.<xref ref-type="bibr" rid="article-22710.r1">[1]</xref><xref ref-type="bibr" rid="article-22710.r67">[67]</xref><xref ref-type="bibr" rid="article-22710.r68">[68]</xref> Urinary cytology has a relatively low sensitivity for low-grade urothelial bladder malignancies.<xref ref-type="bibr" rid="article-22710.r67">[67]</xref><xref ref-type="bibr" rid="article-22710.r68">[68]</xref> Various other biomarkers are available but lack verification from large prospective randomized studies.<xref ref-type="bibr" rid="article-22710.r67">[67]</xref><xref ref-type="bibr" rid="article-22710.r68">[68]</xref>&#x000a0;If a urinary biomarker is done anyway and has a positive result, the patient should be treated as higher risk, and follow-up studies are indicated.<xref ref-type="bibr" rid="article-22710.r67">[67]</xref>&#x000a0;Urine cytology remains the only biomarker that has gained consensus acceptance by guidelines, and even cytology is not recommended for the initial evaluation of asymptomatic patients with microscopic hematuria.<xref ref-type="bibr" rid="article-22710.r1">[1]</xref>&#x000a0;Urine cytology is best used in patients with persistent or recurrent unexplained microscopic hematuria and irritative voiding symptoms or who present with other risk factors for carcinoma in situ.<xref ref-type="bibr" rid="article-22710.r1">[1]</xref></p>
        <p>
<bold>Glomerular Hematuria Evaluation</bold>
</p>
        <p>Glomerular hematuria is suggested by the presence of excessive urinary protein (&#x0003e;500 mg/24 hours), dysmorphic RBCs, or casts, especially red cell casts, particularly if associated with clinical findings such as hypertension, peripheral edema, and "frothy" or "foamy" urine.<xref ref-type="bibr" rid="article-22710.r69">[69]</xref><xref ref-type="bibr" rid="article-22710.r70">[70]</xref>&#x000a0;Dysmorphic RBCs of &#x0003e;25% per HPF have a specificity of &#x0003e;96% with an excellent positive predictive value of 94.6% but low sensitivity (20%)&#x000a0;for glomerulonephritis.<xref ref-type="bibr" rid="article-22710.r71">[71]</xref>&#x000a0;RBC casts are&#x000a0;rare but highly diagnostic and specific for glomerular pathology.<xref ref-type="bibr" rid="article-22710.r69">[69]</xref>&#x000a0;Such patients are usually referred to nephrology for further evaluation, but a risk-based urological evaluation should still be performed.<xref ref-type="bibr" rid="article-22710.r1">[1]</xref></p>
        <p>Glomerulonephritis describes several renal disorders characterized by damage to the glomerular basement membrane, capillary endothelium, or mesangium from abnormal immune system activity.&#x000a0;This damage tends to be progressive, resulting in increasing glomerular damage, tubulointerstitial fibrosis, and reduced plasma filtering ability, eventually resulting in sclerotic glomeruli and renal failure in many cases. This damage is also responsible for the hematuria, proteinuria, red cell casts, and loss of renal function associated with the disorder.&#x000a0;Glomerulonephritis accounts for 10% to 15% of all patients with end-stage renal failure in the US, making it the third most common cause after diabetes and hypertension.<xref ref-type="bibr" rid="article-22710.r41">[41]</xref>&#x000a0;Further evaluation of glomerulonephritis generally includes:</p>
        <list list-type="bullet">
          <list-item>
            <p>Urine collection over 24 hours for urea and creatinine clearance and protein measurement</p>
          </list-item>
          <list-item>
            <p>Antistreptolysin O titer</p>
          </list-item>
          <list-item>
            <p>Autoantibodies (eg, antinuclear, antineutrophil cytoplasmic, antiglomerular basement membrane, and anti-ds-DNA antibodies)</p>
          </list-item>
          <list-item>
            <p>C-reactive protein</p>
          </list-item>
          <list-item>
            <p>Complete blood count (CBC)</p>
          </list-item>
          <list-item>
            <p>Complement (C3, C4 levels)</p>
          </list-item>
          <list-item>
            <p>Cryoglobulins</p>
          </list-item>
          <list-item>
            <p>Immunoglobulins</p>
          </list-item>
          <list-item>
            <p>Liver function</p>
          </list-item>
          <list-item>
            <p>Renal function tests (eg, BUN and creatinine)</p>
          </list-item>
          <list-item>
            <p>Serology for HIV, hepatitis B, and hepatitis C</p>
          </list-item>
          <list-item>
            <p>Serum electrolytes</p>
          </list-item>
          <list-item>
            <p>Serum levels of free light chain immunoglobulins and serum immunofixation</p>
          </list-item>
          <list-item>
            <p>Sickle cell testing (eg, peripheral smear, solubility sickling tests, hemoglobin electrophoresis, isoelectric focusing, high-performance liquid chromatography, PCR-based testing, and genetic testing)</p>
          </list-item>
          <list-item>
            <p>Urine analysis ratios (eg, albumin to creatinine or protein to creatinine ratios)</p>
          </list-item>
          <list-item>
            <p>Urinary Bence-Jones proteins&#x000a0;<xref ref-type="bibr" rid="article-22710.r41">[41]</xref></p>
          </list-item>
        </list>
        <p>Depending on the clinical evaluation and the results from the above, a renal biopsy may be considered.<xref ref-type="bibr" rid="article-22710.r41">[41]</xref><xref ref-type="bibr" rid="article-22710.r72">[72]</xref>&#x000a0;Renal biopsies are often necessary for a definitive diagnosis of glomerulonephritis and related glomerular bleeding.<xref ref-type="bibr" rid="article-22710.r72">[72]</xref> They are typically required when a glomerular source of hematuria appears likely. Although serious complications are rare, renal biopsy can have adverse effects, including life-threatening bleeding. A nephrologist or interventional radiologist usually performs the procedure.<xref ref-type="bibr" rid="article-22710.r72">[72]</xref>&#x000a0;Usually, only 2 or 3 biopsy cores are sufficient for diagnostic purposes. Light and electron microscopy and immunofluorescence are performed to examine the glomerular structure for a specific diagnosis.&#x000a0;</p>
        <p>Glomerulonephritis leads to 10% to 15% of end-stage renal disease cases in the US.<xref ref-type="bibr" rid="article-22710.r41">[41]</xref> In most instances, the disease becomes progressive without timely intervention, eventually leading to morbidity.<xref ref-type="bibr" rid="article-22710.r11">[11]</xref> This makes chronic glomerulonephritis the third most common cause of end-stage renal disease in the US, following diabetes mellitus and hypertension, accounting for 10% of patients on dialysis.<xref ref-type="bibr" rid="article-22710.r41">[41]</xref>&#x000a0;The finding of hematuria together with glomerular podocytopathies (eg, focal segmental glomerulosclerosis, membranous nephropathy, and minimal change disease) is an independent, significant indicator of worse outcomes, more prolonged proteinuria, and increased risk of progressive renal failure.<xref ref-type="bibr" rid="article-22710.r73">[73]</xref>&#x000a0;See StatPearls companion article on "Glomerulonephritis" for additional information.<xref ref-type="bibr" rid="article-22710.r41">[41]</xref></p>
        <p>
<bold>Hematuria in Children</bold>
</p>
        <p>In the pediatric population, gross and microscopic hematuria are relatively common findings with overlapping etiologies.<xref ref-type="bibr" rid="article-22710.r74">[74]</xref>&#x000a0;Normal children will have positive urine dipsticks for hematuria 1% to 4% of the time. Unlike adults, hematuria in children rarely occurs due to an underlying malignancy.<xref ref-type="bibr" rid="article-22710.r75">[75]</xref>&#x000a0;The family history can suggest a possible underlying hereditary&#x000a0;etiology.<xref ref-type="bibr" rid="article-22710.r31">[31]</xref>&#x000a0;Asymptomatic, isolated microscopic hematuria is often idiopathic with no identifiable etiology.<xref ref-type="bibr" rid="article-22710.r74">[74]</xref>&#x000a0;Microscopic hematuria generally suggests an upper urinary tract source, while gross hematuria is more likely from the bladder or urethra.<xref ref-type="bibr" rid="article-22710.r31">[31]</xref><xref ref-type="bibr" rid="article-22710.r75">[75]</xref>&#x000a0;When a specific cause is identified, the most common diagnoses are glomerulonephritis conditions (eg, poststreptococcal or infectious, IgA nephropathy, and thin basement membrane disease), urinary tract infections, or hypercalciuria.<xref ref-type="bibr" rid="article-22710.r74">[74]</xref>&#x000a0;The most common glomerulonephritis in children is poststreptococcal or infectious types.<xref ref-type="bibr" rid="article-22710.r74">[74]</xref><xref ref-type="bibr" rid="article-22710.r75">[75]</xref><xref ref-type="bibr" rid="article-22710.r76">[76]</xref>&#x000a0;Moreover, proteinuria, fluid overload, casts or dysmorphic RBCs on urinary microscopy, brown "cola" colored hematuria, or hypertension suggests glomerular disease in the pediatric age group, just like in adults.<xref ref-type="bibr" rid="article-22710.r74">[74]</xref><xref ref-type="bibr" rid="article-22710.r75">[75]</xref>&#x000a0;</p>
        <p>IgA vasculitis or Hen&#x000f6;ch-Schonlein purpur is rare, with 10 to 20 cases in 100,000 children. It is immune-mediated glomerulonephritis that occurs mainly in children younger than 10 years.<xref ref-type="bibr" rid="article-22710.r77">[77]</xref>&#x000a0;The condition may also affect the gastrointestinal tract, causing bleeding. An infection often precedes hematuria episodes. Renal involvement may be mild or progress to severe crescentic glomerulonephritis.<xref ref-type="bibr" rid="article-22710.r77">[77]</xref>&#x000a0;Initial renal involvement is treated with steroids, but ACEI, immunosuppressants, and plasma exchange may also be used.<xref ref-type="bibr" rid="article-22710.r77">[77]</xref>&#x000a0;The condition is usually self-limited, and only 1% progress to end-stage renal failure.<xref ref-type="bibr" rid="article-22710.r77">[77]</xref>&#x000a0;See StatPearls companion article on "IgA vasculitis."&#x000a0;<xref ref-type="bibr" rid="article-22710.r77">[77]</xref>&#x000a0;Hemolytic uremic syndrome occurs predominantly in childhood and should be suspected in pediatric hematuria cases with anemia, thrombocytopenia, or azotemia.<xref ref-type="bibr" rid="article-22710.r78">[78]</xref><xref ref-type="bibr" rid="article-22710.r79">[79]</xref><xref ref-type="bibr" rid="article-22710.r80">[80]</xref><xref ref-type="bibr" rid="article-22710.r81">[81]</xref>&#x000a0;It occurs in only an estimated 3/100,000 children, follows a bacterial infection often associated with unpasteurized mild or undercooked beef consumption, and may be accompanied by a gastrointestinal disorder.<xref ref-type="bibr" rid="article-22710.r81">[81]</xref>&#x000a0;Treatment is mainly supportive. See our companion StatPearls reference article on "Hemolytic Uremic Syndrome."&#x000a0;<xref ref-type="bibr" rid="article-22710.r81">[81]</xref></p>
      </sec>
      <sec id="article-22710.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Management depends on the underlying etiology. Observation may be a reasonable approach for asymptomatic intermittent hematuria associated with negative imaging, stable renal function, and absence of proteinuria. Overt gross hematuria needs prompt management. Hemodynamic stability should be assured first. Blood products, transfusions, or medications should be utilized to correct any underlying hematological abnormality. In rare instances, interventional radiology-guided embolization may be required to stop life-threatening bleeding from the renal vasculature or for hemorrhagic cystitis refractory to conventional treatments.<xref ref-type="bibr" rid="article-22710.r82">[82]</xref><xref ref-type="bibr" rid="article-22710.r83">[83]</xref></p>
        <p>
<bold>Immediate Management of Significant Gross Hematuria</bold>
</p>
        <p>Significant gross hematuria, especially when associated with urinary difficulty, voiding of clots, clot retention, or severe blood loss, will require immediate treatment with a large (ie, &#x02265;22 French) 3-way Foley catheter placement and continuous bladder irrigation (CBI). Evacuation of clots from the bladder by vigorous hand irrigation or transurethral surgical extraction may be required to control the hematuria. A large 30 cc balloon is not recommended except immediately after transurethral prostate resection.<xref ref-type="bibr" rid="article-22710.r84">[84]</xref>&#x000a0;Anticoagulant therapy should be stopped or reversed when possible.&#x000a0;If all the clots from the bladder are not evacuated and removed, the Foley catheter will likely become clogged, and the clot breakdown products from urokinase activity will act as natural anticoagulants, prolonging the bleeding.</p>
        <p>The need to take a patient to the operating room for electrocautery or laser ablation with clot evacuation when initial manual irrigation is unsuccessful can sometimes be avoided by using chemical thrombolysis. The following techniques successfully soften and dissolve retained clots in the bladder, allowing them to be evacuated through the catheter and avoiding surgical clot evacuation.<xref ref-type="bibr" rid="article-22710.r85">[85]</xref><xref ref-type="bibr" rid="article-22710.r86">[86]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Instill 40,000 units of chymotrypsin in 50 mL of 5% sodium bicarbonate solution with a large 22- to 24-French Foley catheter and leave it in the bladder for 30 minutes.<xref ref-type="bibr" rid="article-22710.r85">[85]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Instill 30 to 50 mL of a hydrogen peroxide irrigation solution with a 1:5 mixture of 3% hydrogen peroxide and 0.9% saline into the bladder and left there for 3 to 5 minutes. The bladder is then manually irrigated and evacuated. The process is then repeated with another installation of the hydrogen peroxide solution placed into the bladder.<xref ref-type="bibr" rid="article-22710.r86">[86]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Administer limited palliative radiation therapy in selected cases of otherwise intractable hematuria if ionizing radiation has not been previously utilized.<xref ref-type="bibr" rid="article-22710.r87">[87]</xref><xref ref-type="bibr" rid="article-22710.r88">[88]</xref><xref ref-type="bibr" rid="article-22710.r89">[89]</xref><xref ref-type="bibr" rid="article-22710.r90">[90]</xref><xref ref-type="bibr" rid="article-22710.r91">[91]</xref><xref ref-type="bibr" rid="article-22710.r92">[92]</xref><xref ref-type="bibr" rid="article-22710.r93">[93]</xref><xref ref-type="bibr" rid="article-22710.r94">[94]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Superselectively embolize a vesicle branch of the hypogastric or prostatic artery in otherwise intractable cases.<xref ref-type="bibr" rid="article-22710.r95">[95]</xref><xref ref-type="bibr" rid="article-22710.r96">[96]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Place a nephrostomy tube for supravesical urinary diversion and interventional radiological superselective embolization of the prostatic artery or the anterior branch of the internal iliac artery.<xref ref-type="bibr" rid="article-22710.r95">[95]</xref><xref ref-type="bibr" rid="article-22710.r96">[96]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Perform a cystectomy with urinary diversion as a&#x000a0;final treatment of last resort.</p>
          </list-item>
        </list>
        <p>Controlling bleeding from hemorrhagic cystitis can be particularly challenging, most often seen after pelvic irradiation (ie, radiation cystitis) or after chemotherapy, particularly with oxazaphosphorines (eg, cyclophosphamide, ifosfamide, and trofosfamide.)&#x000a0;Treatment selection typically starts with the least invasive therapy and progresses as necessary.&#x000a0;Therapy starts as above but may require intravesical therapy with alum, aminocaproic acid, formalin, prostaglandins, or silver nitrate solutions.<xref ref-type="bibr" rid="article-22710.r97">[97]</xref><xref ref-type="bibr" rid="article-22710.r98">[98]</xref><xref ref-type="bibr" rid="article-22710.r99">[99]</xref>&#x000a0;Of these, formalin is the most toxic to the bladder mucosa and is therefore reserved as one of the final options.<xref ref-type="bibr" rid="article-22710.r97">[97]</xref><xref ref-type="bibr" rid="article-22710.r100">[100]</xref><xref ref-type="bibr" rid="article-22710.r101">[101]</xref><xref ref-type="bibr" rid="article-22710.r102">[102]</xref>&#x000a0;Hyperbaric oxygen therapy with or without oral pentosan polysulfate can be used and is particularly helpful with radiation-induced hemorrhagic cystitis.<xref ref-type="bibr" rid="article-22710.r103">[103]</xref><xref ref-type="bibr" rid="article-22710.r104">[104]</xref>&#x000a0;See StatPearls companion article on "Radiation Cystitis and Hyperbaric Management" for additional information on hyperbaric management.<xref ref-type="bibr" rid="article-22710.r103">[103]</xref>&#x000a0;</p>
        <p>More invasive surgical options include nephrostomy tube placement for supravesical urinary diversion and interventional radiological superselective embolization of the prostatic artery or the anterior branch of the internal iliac artery.<xref ref-type="bibr" rid="article-22710.r95">[95]</xref><xref ref-type="bibr" rid="article-22710.r96">[96]</xref>&#x000a0;The final treatment of last resort would be a cystectomy with urinary diversion. Treatment selection typically starts with the least invasive therapy and progresses as necessary.</p>
        <p><bold>Nonglomerular Hematuria</bold>&#x000a0;<bold>Management</bold></p>
        <p>The management approach selected depends on the underlying etiology of nonglomerular hematuria. Acute urinary tract infections are treated with 3 to 7 days of first-line antibiotics.<xref ref-type="bibr" rid="article-22710.r72">[72]</xref>&#x000a0;Complicated infections will take longer to resolve.<xref ref-type="bibr" rid="article-22710.r105">[105]</xref>&#x000a0;Bleeding from radiation cystitis can benefit from pentosan polysulfate administration, transurethral electrofulguration/laser treatment, intravesical instillations (silver nitrate, formalin, or alum), or hyperbaric oxygen therapy.<xref ref-type="bibr" rid="article-22710.r83">[83]</xref><xref ref-type="bibr" rid="article-22710.r98">[98]</xref>&#x000a0;Severe hemorrhagic cystitis may require transurethral surgery or intravesical instillations (eg, silver nitrate, formalin, or alum).<xref ref-type="bibr" rid="article-22710.r83">[83]</xref>&#x000a0;Intractable cases of severe hemorrhagic or radiation cystitis may require a cystectomy.&#x000a0;Genitourinary trauma will require specific therapy depending on the hemodynamic stability of the patient and the severity and location of the injury. Most renal injuries can be managed conservatively if the patient is hemodynamically stable.<xref ref-type="bibr" rid="article-22710.r27">[27]</xref>&#x000a0;Ureteral trauma is uncommon and will often heal with stenting but may require surgical repair.<xref ref-type="bibr" rid="article-22710.r59">[59]</xref><xref ref-type="bibr" rid="article-22710.r60">[60]</xref>&#x000a0;Intraperitoneal bladder ruptures typically need immediate surgery, but extraperitoneal leakages will often heal with catheter drainage alone.<xref ref-type="bibr" rid="article-22710.r59">[59]</xref><xref ref-type="bibr" rid="article-22710.r60">[60]</xref>&#x000a0;Urethral injuries may need to be surgically repaired, either immediately or after a reasonable delay of 2 to 3 months, using suprapubic drainage in the interim.<xref ref-type="bibr" rid="article-22710.r106">[106]</xref>&#x000a0;Postprocedural hematuria can usually be managed conservatively or with a Foley catheter and irrigation as appropriate.</p>
        <p>Severe bleeding from the prostate can generally be controlled with a standard Foley catheter or a 3-way catheter with continuous bladder irrigation. If this is not adequate, transurethral fulguration,&#x000a0;selective prostatic artery embolization, or even a brief course of palliative radiation therapy may be used.<xref ref-type="bibr" rid="article-22710.r87">[87]</xref><xref ref-type="bibr" rid="article-22710.r88">[88]</xref><xref ref-type="bibr" rid="article-22710.r89">[89]</xref><xref ref-type="bibr" rid="article-22710.r90">[90]</xref><xref ref-type="bibr" rid="article-22710.r91">[91]</xref><xref ref-type="bibr" rid="article-22710.r92">[92]</xref><xref ref-type="bibr" rid="article-22710.r95">[95]</xref><xref ref-type="bibr" rid="article-22710.r96">[96]</xref>&#x000a0;Less severe hematuria from the prostate can often be managed with 5-alpha reductase inhibitors (eg, finasteride and dutasteride).<xref ref-type="bibr" rid="article-22710.r107">[107]</xref><xref ref-type="bibr" rid="article-22710.r108">[108]</xref></p>
        <p>Nephrolithiasis management is generally supportive, emphasizing pain control, avoiding or treating infection, facilitating stone passage, and administering adequate fluids.&#x000a0;Kidney stone size and location may warrant further management.<xref ref-type="bibr" rid="article-22710.r109">[109]</xref>&#x000a0;Approximately 90% of stones smaller than 4 mm will pass spontaneously. Larger symptomatic stones may require lithotripsy, ureteroscopy, or percutaneous surgery.<xref ref-type="bibr" rid="article-22710.r55">[55]</xref><xref ref-type="bibr" rid="article-22710.r110">[110]</xref>&#x000a0;If complicated by a simultaneous urinary tract infection, preliminary drainage with a nephrostomy or double-J stent will most likely be required until the infection is eliminated and definitive stone treatment can be undertaken.<xref ref-type="bibr" rid="article-22710.r55">[55]</xref><xref ref-type="bibr" rid="article-22710.r111">[111]</xref><xref ref-type="bibr" rid="article-22710.r112">[112]</xref></p>
        <p>Renal cell carcinoma, other malignancies confined to the kidneys, and renal pelvic urothelial cancers will require surgery and possible nephrectomy or nephroureterectomy.<xref ref-type="bibr" rid="article-22710.r113">[113]</xref>&#x000a0;Palliative radiation therapy or selective renal arterial branch embolization for hematuria control can be considered in selected patients with bleeding from a kidney.<xref ref-type="bibr" rid="article-22710.r87">[87]</xref><xref ref-type="bibr" rid="article-22710.r93">[93]</xref><xref ref-type="bibr" rid="article-22710.r94">[94]</xref>&#x000a0;Various benign renal neoplasms (angiomyolipomas, oncocytomas) may also cause hematuria and require surgical ablation, medical therapy, embolization, or other surgery.<xref ref-type="bibr" rid="article-22710.r114">[114]</xref><xref ref-type="bibr" rid="article-22710.r115">[115]</xref>&#x000a0;Transitional cell&#x000a0;carcinoma can occur anywhere in the genitourinary tract but is most often found in the bladder. Transurethral resection of the tumor and periodic cystoscopies are the standard recommended therapy. Invasive bladder cancers may require a cystectomy, and high-grade carcinoma-in-situ of the bladder will require intravesical BCG therapy.<xref ref-type="bibr" rid="article-22710.r116">[116]</xref><xref ref-type="bibr" rid="article-22710.r117">[117]</xref>&#x000a0;Metastatic cancers will need staging as well as further individualized oncological and radiotherapy or surgical management.&#x000a0;</p>
        <p><bold>Glomerular Hematuria</bold>&#x000a0;<bold>Management</bold></p>
        <p>The management approach for glomerular hematuria also depends on the underlying cause and the effect on renal function. Some hereditary diseases, like Alport syndrome, thin basement membrane disease, and polycystic kidney disease, require regular monitoring of renal function and periodic follow-up examinations. Poststreptococcal glomerulonephritis requires supportive care, and IgA nephropathy treatment depends on the degree of proteinuria and renal function.<xref ref-type="bibr" rid="article-22710.r41">[41]</xref>&#x000a0;Relatively normal creatinine with minimal proteinuria may be managed conservatively. High-risk features, including rising creatinine levels, persistent proteinuria of &#x0003e;1 g/day, and active disease on renal biopsy, are indications to consider immunosuppressive therapy.<xref ref-type="bibr" rid="article-22710.r118">[118]</xref>&#x000a0;Nephrotic syndrome and other etiologies generally necessitate a nephrology consultation for further management. See our companion StatPearls reference article on "Nephrotic Syndrome."<xref ref-type="bibr" rid="article-22710.r119">[119]</xref>&#x000a0;General treatment for most glomerulopathies includes angiotensin-converting enzyme inhibitors (ACE-I) or angiotensin 2 receptor blockers (ARB), which help control hypertension, reduce proteinuria, and slow disease progression.<xref ref-type="bibr" rid="article-22710.r41">[41]</xref></p>
        <p>The following management approaches are recommended for these inheritable or genetic glomerular disorders:</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Alport syndrome</bold>: This is a hereditary disorder of type IV collagen production affecting the renal glomerular basement membranes, eyes, and ears, which is characterized&#x000a0;by progressive renal failure, bilateral sensorineural hearing loss, and eye abnormalities. Alport syndrome eventually produces proteinuria, hypertension, progressive azotemia, and end-stage renal disease.<xref ref-type="bibr" rid="article-22710.r120">[120]</xref><xref ref-type="bibr" rid="article-22710.r121">[121]</xref><xref ref-type="bibr" rid="article-22710.r122">[122]</xref> In addition to ACEI or ARB medications, adding a statin and a non-dihydropyridine calcium channel blocker appears helpful. One study shows that ramipril can decrease disease progression in children by almost half.<xref ref-type="bibr" rid="article-22710.r123">[123]</xref>&#x000a0;The condition tends to be progressive and may eventually require dialysis or renal transplantation.<xref ref-type="bibr" rid="article-22710.r120">[120]</xref>&#x000a0;See our companion StatPearls reference article on "Alport Syndrome."<xref ref-type="bibr" rid="article-22710.r120">[120]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Pierson syndrome</bold>: This rare syndrome&#x000a0;is very similar to Alport syndrome. Pierson syndrome mainly affects the eyes and kidneys, resulting in microcoria, visual problems, and congenital nephrotic syndrome, which is progressive. Hypotonic musculature and blindness may also develop.<xref ref-type="bibr" rid="article-22710.r124">[124]</xref><xref ref-type="bibr" rid="article-22710.r125">[125]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Polycystic kidney</bold>
<bold>disease</bold>:&#x000a0;&#x000a0;Polycystic kidney disease (PKD) is the most common genetic cause of end-stage renal failure in the adult population and accounts for 6% to 8% of patients on dialysis.<xref ref-type="bibr" rid="article-22710.r26">[26]</xref>&#x000a0;Fifty percent of patients will need kidney replacement therapy by the age of 60 years.&#x000a0;Cyst aspiration with ultrasound or CT guidance can be used for pain from large cysts distorting the genitourinary system. Laparoscopic surgical cyst fenestration may also help. Polycystic kidney disease has no specific treatment; if it progresses to end-stage renal failure, dialysis or renal transplantation can be performed. Nephrectomy is usually recommended at that point.<xref ref-type="bibr" rid="article-22710.r26">[26]</xref>&#x000a0;Approximately 20% of patients with polycystic kidney disease will develop nephrolithiasis.<xref ref-type="bibr" rid="article-22710.r26">[26]</xref><xref ref-type="bibr" rid="article-22710.r126">[126]</xref>&#x000a0;See&#x000a0; StatPearls companion article on "Polycystic Kidney Disease" for additional management details.<xref ref-type="bibr" rid="article-22710.r26">[26]</xref><xref ref-type="bibr" rid="article-22710.r126">[126]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Thin basement membrane</bold>
<bold>disease</bold>: Formerly known as&#x000a0;familial benign hematuria, this&#x000a0;relatively common hereditary renal disorder may present in 5% to 9% of adults.<xref ref-type="bibr" rid="article-22710.r127">[127]</xref><xref ref-type="bibr" rid="article-22710.r128">[128]</xref><xref ref-type="bibr" rid="article-22710.r129">[129]</xref>&#x000a0;The finding of diffuse thinning of the glomerular basement membrane on electron microscopy of a renal biopsy is diagnostic. A history of familial hematuria is present in 30% to 50% of cases. This disorder is sometimes associated with focal segmental glomerulosclerosis.<xref ref-type="bibr" rid="article-22710.r130">[130]</xref>&#x000a0;Thin basement membrane disease may be a less severe form of Alport syndrome as both involve thinning the glomerular basement membrane.<xref ref-type="bibr" rid="article-22710.r131">[131]</xref><xref ref-type="bibr" rid="article-22710.r132">[132]</xref>&#x000a0;The diagnosis of thin basement membrane disease is usually suggested by a benign course, lack of proteinuria, and a positive family history of hematuria without renal failure. In the absence of proteinuria, hypertension, peripheral edema, or renal failure, a renal biopsy may not be required. No treatment is usually necessary as it typically has a benign course, although significant proteinuria and a family history of renal failure suggest a more guarded prognosis.<xref ref-type="bibr" rid="article-22710.r133">[133]</xref><xref ref-type="bibr" rid="article-22710.r134">[134]</xref>&#x000a0;Close monitoring and follow-up examinations are suggested.<xref ref-type="bibr" rid="article-22710.r133">[133]</xref><xref ref-type="bibr" rid="article-22710.r134">[134]</xref>&#x000a0;See the companion StatPearls article on "Thin Basement Membrane Disease" for additional information.<xref ref-type="bibr" rid="article-22710.r134">[134]</xref></p>
          </list-item>
        </list>
        <p>In addition to angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers, autoimmune glomerular disorders often require additional therapies. Corticosteroids are used in some cases, especially if there is excessive proteinuria.<xref ref-type="bibr" rid="article-22710.r41">[41]</xref><xref ref-type="bibr" rid="article-22710.r135">[135]</xref>&#x000a0;Rituximab is a monoclonal immunosuppressive antibody that lyses B-lymphocytes.<xref ref-type="bibr" rid="article-22710.r136">[136]</xref>&#x000a0;It is most useful in membranoproliferative glomerulonephritis, lupus nephritis, and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides.<xref ref-type="bibr" rid="article-22710.r136">[136]</xref><xref ref-type="bibr" rid="article-22710.r137">[137]</xref>&#x000a0;Cytotoxic agents (eg, cyclophosphamide and methotrexate) may be used, as well as plasma exchange and calcineurin inhibitors, which reduce T-cell activity.<xref ref-type="bibr" rid="article-22710.r41">[41]</xref>&#x000a0;See the companion StatPearls article on "Glomerulonephritis."<xref ref-type="bibr" rid="article-22710.r41">[41]</xref>&#x000a0;The following management approaches are recommended for these autoimmune glomerular disorders:</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>IgA</bold>
<bold>nephropathy</bold>: Also known as Berger disease, this condition is a common cause of microscopic hematuria worldwide that usually presents initially with painless, intermittent gross hematuria often related to upper respiratory infections, which progresses to persistent microhematuria. IgA nephropathy is slightly more common in Whites and males. Progression to chronic renal failure may occur in up to 20% of cases, typically taking 10 years or longer from the initial diagnosis.<xref ref-type="bibr" rid="article-22710.r138">[138]</xref><xref ref-type="bibr" rid="article-22710.r139">[139]</xref>&#x000a0;Treatment involves ACEI or ARB and corticosteroids if there is excessive proteinuria.<xref ref-type="bibr" rid="article-22710.r41">[41]</xref><xref ref-type="bibr" rid="article-22710.r138">[138]</xref><xref ref-type="bibr" rid="article-22710.r139">[139]</xref>&#x000a0;See the companion StatPearls articles on "IgA Nephropathy" and "Berger Disease" for additional management information.<xref ref-type="bibr" rid="article-22710.r138">[138]</xref><xref ref-type="bibr" rid="article-22710.r139">[139]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Crescentic glomerulonephritis</bold>: Also known as rapidly progressive glomerulonephritis, crescentic glomerulonephritis is an autoimmune disorder characterized by the presence of extensive glomerular crescents, usually &#x0003e;50% formed of infiltrating macrophages and proliferating epithelial cells from the lining of Bowman's capsule. This condition tends to cause a quick decline in renal function, which accounts for its other name, "rapidly progressive."<xref ref-type="bibr" rid="article-22710.r133">[133]</xref><xref ref-type="bibr" rid="article-22710.r140">[140]</xref>&#x000a0;Crescentic glomerulonephritis may also be an associated complication of other glomerular disorders.&#x000a0;Initial treatment is glucocorticoids and cyclophosphamide or possibly rituximab in selected patients. Plasma exchange has been useful in some patients. Maintenance therapy may consist of the&#x000a0;immunosuppressive azathioprine, methotrexate, or rituximab.<xref ref-type="bibr" rid="article-22710.r133">[133]</xref><xref ref-type="bibr" rid="article-22710.r140">[140]</xref>&#x000a0;See the companion StatPearls article "Crescentic Glomerulonephritis" for additional management information.<xref ref-type="bibr" rid="article-22710.r140">[140]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Diffuse proliferative glomerulonephritis</bold>: A condition often associated with lupus nephritis, the severity of diffuse proliferative glomerulonephritis<bold>&#x000a0;</bold>can vary widely.<xref ref-type="bibr" rid="article-22710.r141">[141]</xref><xref ref-type="bibr" rid="article-22710.r142">[142]</xref>&#x000a0;Standard treatment includes ACEI or ARB plus statins due to the high rate of cardiovascular atherosclerosis.<xref ref-type="bibr" rid="article-22710.r142">[142]</xref> More severe disease is treated with corticosteroids. If unresponsive to steroids, calcineurin inhibitors (eg, tacrolimus) can be added. Plasmapheresis, mycophenolate mofetil, and cyclophosphamide are used in selected cases.<xref ref-type="bibr" rid="article-22710.r142">[142]</xref>&#x000a0;See the companion StatPearls articles on "Diffuse Proliferative Glomerulonephritis" and "Lupus Nephritis" for additional information.<xref ref-type="bibr" rid="article-22710.r141">[141]</xref><xref ref-type="bibr" rid="article-22710.r142">[142]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Antiglomerular basement membrane disease</bold>:&#x000a0;Also known as&#x000a0;Goodpasture syndrome, this condition affects the lungs and kidneys significantly. While there is a genetic predisposition to antiglomerular basement membrane disease (anti-GBM disease), there is usually some additional triggering event to the alveolar capillaries from drugs, medical procedures, or toxic exposure.<xref ref-type="bibr" rid="article-22710.r33">[33]</xref>&#x000a0;Anti-GBM disease accounts for about 10% to 20% of all cases of crescentic glomerulonephritis. Patients often present critically ill; initial therapy includes prednisone, cyclophosphamide, and daily plasmapheresis. The associated alveolar hemorrhage, which may be life-threatening, is treated with steroids.<xref ref-type="bibr" rid="article-22710.r33">[33]</xref>&#x000a0;Rituximab has also been used successfully in these patients.<xref ref-type="bibr" rid="article-22710.r143">[143]</xref>&#x000a0;See the companion StatPearls article on "Goodpasture Syndrome."<xref ref-type="bibr" rid="article-22710.r33">[33]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Hepatitis-related nephropathy</bold>: This autoimmune glomerular disorder can present as membranoproliferative glomerulonephritis or mixed cryoglobulinemia. Treatment is similar to other autoimmune and postinfectious glomerulopathies with the addition of appropriate antiviral therapy.<xref ref-type="bibr" rid="article-22710.r144">[144]</xref><xref ref-type="bibr" rid="article-22710.r145">[145]</xref><xref ref-type="bibr" rid="article-22710.r146">[146]</xref><xref ref-type="bibr" rid="article-22710.r147">[147]</xref><xref ref-type="bibr" rid="article-22710.r148">[148]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Membranous glomerulonephritis</bold>: A&#x000a0;common cause of nephrotic syndrome worldwide, membranous glomerulonephritis is characterized by immune complex deposition underneath the subepithelial podocytes of the glomerular capillaries. Its etiology is an autoimmune antibody or antigen reaction to the podocytes.&#x000a0;About 12 million people are diagnosed with membranous glomerulopathy annually in the US.<xref ref-type="bibr" rid="article-22710.r149">[149]</xref>&#x000a0;Systemic lupus erythematosus is the most common cause of secondary membranous nephropathy. Classified as type V lupus nephritis, the usual nephrotic-range proteinuria common to primary membranous nephropathy is accompanied by significant hematuria and hypertension.&#x000a0;Kidney biopsy will show staining positive for all 3 Ig types (IgG, IgM, IgA), as well as C3 and C1q. Treatment is similar to other autoimmune glomerular disorders and starts with ACEI and ARB drugs. Immunosuppressives, steroids, cyclophosphamide, calcineurin inhibitors, and rituximab may also be used.<xref ref-type="bibr" rid="article-22710.r150">[150]</xref>&#x000a0;See the companion StatPearls article "Membranous Nephropathy" for additional management information.<xref ref-type="bibr" rid="article-22710.r151">[151]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Poststreptococcal</bold>
<bold>glomerulonephritis</bold>: This condition typically appears within 6 weeks of a streptococcal skin infection but only 1 to 2 weeks after a streptococcal sore throat. The inflammatory response to the streptococcal infection results in a significant autoimmune reaction, frequently resulting in a rapid decline in renal function.<xref ref-type="bibr" rid="article-22710.r152">[152]</xref>&#x000a0;Symptoms may include gross hematuria (seen in 30%-50% of cases), oliguria, hypertension, peripheral edema found in 65% to 90% of cases, and proteinuria.<xref ref-type="bibr" rid="article-22710.r152">[152]</xref> Skin infections are becoming a more common etiology, although the overall incidence of poststreptococcal glomerulonephritis is declining in developed countries. Even so, poststreptococcal glomerulonephritis remains the most common cause of glomerulonephritis in children, even in the US.<xref ref-type="bibr" rid="article-22710.r74">[74]</xref>&#x000a0;Worldwide, 97% of cases are found in underdeveloped regions.<xref ref-type="bibr" rid="article-22710.r152">[152]</xref>&#x000a0;Treatment involves supportive therapy along with antibiotics. Furosemide is preferred over thiazides for controlling hypertension and edema, along with fluid and salt restriction.<xref ref-type="bibr" rid="article-22710.r152">[152]</xref>&#x000a0;ACEI or ARBs are also recommended, and calcium channel blockers may be used if necessary.<xref ref-type="bibr" rid="article-22710.r152">[152]</xref>&#x000a0;Corticosteroids are reserved for patients who develop kidney failure or have crescents on renal biopsy, while immunosuppression does not appear to be helpful in this disorder.<xref ref-type="bibr" rid="article-22710.r152">[152]</xref> Dialysis is reserved for only the most severe cases. See StatPearls companion article "Poststreptococcal Glomerulonephritis" for additional information.<xref ref-type="bibr" rid="article-22710.r152">[152]</xref>&#x000a0;</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-22710.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The differential diagnosis of hematuria includes etiologies that cause the appearance of discolored red, pink, brown, or yellow urine, including:</p>
        <list list-type="bullet">
          <list-item>
            <p>Alkaptonuria</p>
          </list-item>
          <list-item>
            <p>Bile pigments in urine</p>
          </list-item>
          <list-item>
            <p>Drug effects</p>
          </list-item>
          <list-item>
            <p>False positive urine dipstick test not confirmed by microscopy</p>
          </list-item>
          <list-item>
            <p>Hemoglobinuria</p>
          </list-item>
          <list-item>
            <p>Hemolytic anemias</p>
          </list-item>
          <list-item>
            <p>Porphyria</p>
          </list-item>
          <list-item>
            <p>Rhabdomyolysis</p>
          </list-item>
          <list-item>
            <p>Phenazopyridine use</p>
          </list-item>
          <list-item>
            <p>Various foods (eg, beets, blackberries, and fava beans)&#x000a0;</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-22710.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Children with isolated hematuria generally have a good outcome, but the presence of proteinuria, hypertension, or abnormal renal function suggests a glomerular etiology and may lead to a more guarded prognosis.&#x000a0;In adults, unexplained hematuria, especially gross hematuria, should always be taken seriously because it may signal a urinary tract malignancy.&#x000a0;Nonglomerular hematuria usually has a favorable prognosis, as most etiologies have specific remedies and treatments.&#x000a0;Treatment options are less effective and more limited in genetic glomerulopathies, which may be progressive, resulting in end-stage renal failure.&#x000a0;Thin basement membrane disease, formerly called benign familial hematuria, has an excellent prognosis and requires no specific treatment.&#x000a0;Early diagnosis and optimal therapy can help minimize poor outcomes and preserve renal function.&#x000a0;</p>
      </sec>
      <sec id="article-22710.s11" sec-type="Complications">
        <title>Complications</title>
        <p>The following issues and complications can be associated with hematuria:</p>
        <list list-type="bullet">
          <list-item>
            <p>False positives are common if microscopic urinalyses are not used to confirm positive dipstick findings for hematuria. This causes costly, unnecessary evaluations and consultations.</p>
          </list-item>
          <list-item>
            <p>Failure to properly evaluate or treat hematuria may result in catastrophic or life-threatening disease.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Some conditions may result in progressive loss of renal function, leading to end-stage renal failure.</p>
          </list-item>
          <list-item>
            <p>Even in these severe cases, patients can still be treated with dialysis or renal transplantation, which may result in associated postsurgical complications (eg, infection, wound dehiscence, and transplantation rejection).</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-22710.s12" sec-type="Postoperative and Rehabilitation Care">
        <title>Postoperative and Rehabilitation Care</title>
        <p>Key points clinicians should keep in mind for ongoing management of hematuria include:</p>
        <list list-type="bullet">
          <list-item>
            <p>A low-sodium diet is recommended in patients with hypertension and hematuria.</p>
          </list-item>
          <list-item>
            <p>Statins are often recommended in patients with glomerulonephritis to help deal with hypertension and progressive atherosclerosis.</p>
          </list-item>
          <list-item>
            <p>Routine monitoring and follow-up testing are recommended for many etiologies of hematuria.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-22710.s13" sec-type="Consultations">
        <title>Consultations</title>
        <p>Nephrology consultation should be considered if there are dysmorphic RBCs, cellular casts, especially red-cell casts, abnormal renal function, or significant proteinuria.&#x000a0;Urology should be involved in all gross or unexplained microscopic hematuria cases, mainly if associated with urinary symptoms suggestive of BPH, nephrolithiasis, or any urinary tract neoplasms.</p>
      </sec>
      <sec id="article-22710.s14" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Hematuria is a common problem that may portend possible pathology such as urinary calculi or malignancies. Most of the time, the evaluation is negative, which should be considered reassuring. The recommended criteria of &#x02265;3 RBC/HPF on microscopic urinalysis should be followed to avoid unnecessary testing and patient anxiety.</p>
      </sec>
      <sec id="article-22710.s15" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>Key factors to bear in mind when managing gross and microscopic hematuria include:</p>
        <list list-type="bullet">
          <list-item>
            <p>A dipstick evaluation of hematuria is not reliable. A microscopic urinalysis of a properly obtained urine sample showing &#x0003e;3 RBC/HPF is sufficient to warrant further evaluation.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Patients on anticoagulants who develop hematuria still need a full and proper evaluation.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Female patients with hematuria are the most likely to receive inadequate or incomplete evaluations, most likely due to their high incidence of UTIs and potential contamination of the urine from vaginal bleeding. It is vital, possibly life-saving, to perform follow-up urinalyses in such patients to identify those with persistent microhematuria requiring further evaluation.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>In patients who present with hematuria and UTI, the resolution of hematuria tested at least 6 weeks after antibiotic treatment should be documented, as UTI and malignancy can coexist.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>The initial classification of hematuria should be:
<list list-type="bullet"><list-item><p>Microscopic or gross</p></list-item><list-item><p>Nonglomerular, which has normal RBCs on microscopic examination or glomerular characterized by proteinuria, dysmorphic RBCs, red-cell or other casts, azotemia, edema, "cola-colored" or "frothy" urine</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Nonglomerular microhematuria is further classified as low-, intermediate-, or high-risk to help guide the workup.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>If the patient does not fit the risk stratification categories, they should be treated as belonging to the next higher-risk category.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Even if the initial impression is a glomerular cause, a urological risk-stratified evaluation should still be performed.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Cystoscopy, along with possible CT urogram or retrograde pyelogram, is the definitive test for bladder cancer.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Consider adding a statin to patients with glomerular disease such as glomerulonephritis to minimize the progression of atherosclerosis.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>The development of unexplained gross hematuria automatically upgrades the patient to the high-risk category, even if previously evaluated with negative findings.&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Consider IgA vasculitis and hemolytic uremic syndrome for unexplained hematuria in children, primarily when associated with a predisposing infection, renal failure, anemia, or thrombocytopenia.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>In managing urinary clot retention, consider using the&#x000a0;chymotrypsin/sodium bicarbonate or diluted hydrogen peroxide irrigation solutions for thrombus dissolution, described earlier, which may help avoid surgical clot evacuation in the OR.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>When more straightforward options are unsuccessful, consider intravesical therapy, selective arterial embolization, and palliative radiation therapy for the control of otherwise intractable hematuria.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Check a coagulation profile for patients with unexplained hematuria who might have a coagulopathy.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-22710.s16" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Managing gross and microscopic hematuria necessitates a coordinated effort among healthcare professionals to ensure patient-centered care and optimal outcomes. Given its multifactorial etiology, an interprofessional team led by primary care or emergency physicians spearheads the initial assessment. Referral to nephrologists or urologists may follow, dictated by severity and risk factors. Nurse practitioners are pivotal in educating parents on managing hematuria in children, while pharmacists contribute by informing patients about medication-related risks. Effective communication within the team is crucial to expedite appropriate workup, especially concerning potential malignancies. Patient education and seamless interprofessional communication are paramount for achieving favorable clinical outcomes in hematuria management.</p>
      </sec>
      <sec id="article-22710.s17">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=22710&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=22710">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/kidney-health/gross-and-microscopic-hematuria/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=22710">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/22710/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=22710">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-22710.s18">
        <title>References</title>
        <ref id="article-22710.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barocas</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Boorjian</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Alvarez</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Downs</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Gross</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Hamilton</surname>
                <given-names>BD</given-names>
              </name>
              <name>
                <surname>Kobashi</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Lipman</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Lotan</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ng</surname>
                <given-names>CK</given-names>
              </name>
              <name>
                <surname>Nielsen</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Peterson</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Raman</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Smith-Bindman</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Souter</surname>
                <given-names>LH</given-names>
              </name>
            </person-group>
            <article-title>Microhematuria: AUA/SUFU Guideline.</article-title>
            <source>J Urol</source>
            <year>2020</year>
            <month>Oct</month>
            <volume>204</volume>
            <issue>4</issue>
            <fpage>778</fpage>
            <page-range>778-786</page-range>
            <pub-id pub-id-type="pmid">32698717</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mariani</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Mariani</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Macchioni</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Stams</surname>
                <given-names>UK</given-names>
              </name>
              <name>
                <surname>Hariharan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Moriera</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>The significance of adult hematuria: 1,000 hematuria evaluations including a risk-benefit and cost-effectiveness analysis.</article-title>
            <source>J Urol</source>
            <year>1989</year>
            <month>Feb</month>
            <volume>141</volume>
            <issue>2</issue>
            <fpage>350</fpage>
            <page-range>350-5</page-range>
            <pub-id pub-id-type="pmid">2492350</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Davis</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Barocas</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Castle</surname>
                <given-names>EP</given-names>
              </name>
              <name>
                <surname>Lang</surname>
                <given-names>EK</given-names>
              </name>
              <name>
                <surname>Leveillee</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Messing</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Peterson</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Turk</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Weitzel</surname>
                <given-names>W</given-names>
              </name>
              <collab>American Urological Association</collab>
            </person-group>
            <article-title>Diagnosis, evaluation and follow-up of asymptomatic microhematuria (AMH) in adults: AUA guideline.</article-title>
            <source>J Urol</source>
            <year>2012</year>
            <month>Dec</month>
            <volume>188</volume>
            <issue>6 Suppl</issue>
            <fpage>2473</fpage>
            <page-range>2473-81</page-range>
            <pub-id pub-id-type="pmid">23098784</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Matulewicz</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>DeLancey</surname>
                <given-names>JO</given-names>
              </name>
              <name>
                <surname>Pavey</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Schaeffer</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Popescu</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Meeks</surname>
                <given-names>JJ</given-names>
              </name>
            </person-group>
            <article-title>Dipstick Urinalysis as a Test for Microhematuria and Occult Bladder Cancer.</article-title>
            <source>Bladder Cancer</source>
            <year>2017</year>
            <month>Jan</month>
            <day>27</day>
            <volume>3</volume>
            <issue>1</issue>
            <fpage>45</fpage>
            <page-range>45-49</page-range>
            <pub-id pub-id-type="pmid">28149934</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ingelfinger</surname>
                <given-names>JR</given-names>
              </name>
            </person-group>
            <article-title>Hematuria in Adults.</article-title>
            <source>N Engl J Med</source>
            <year>2021</year>
            <month>Jul</month>
            <day>08</day>
            <volume>385</volume>
            <issue>2</issue>
            <fpage>153</fpage>
            <page-range>153-163</page-range>
            <pub-id pub-id-type="pmid">34233098</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Grossfeld</surname>
                <given-names>GD</given-names>
              </name>
              <name>
                <surname>Litwin</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Wolf</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Hricak</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Shuler</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Agerter</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Carroll</surname>
                <given-names>PR</given-names>
              </name>
            </person-group>
            <article-title>Evaluation of asymptomatic microscopic hematuria in adults: the American Urological Association best practice policy--part I: definition, detection, prevalence, and etiology.</article-title>
            <source>Urology</source>
            <year>2001</year>
            <month>Apr</month>
            <volume>57</volume>
            <issue>4</issue>
            <fpage>599</fpage>
            <page-range>599-603</page-range>
            <pub-id pub-id-type="pmid">11306356</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sutton</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Evaluation of hematuria in adults.</article-title>
            <source>JAMA</source>
            <year>1990</year>
            <month>May</month>
            <day>09</day>
            <volume>263</volume>
            <issue>18</issue>
            <fpage>2475</fpage>
            <page-range>2475-80</page-range>
            <pub-id pub-id-type="pmid">2184261</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Adams</surname>
                <given-names>EC</given-names>
              </name>
            </person-group>
            <article-title>Differentiation of myoglobin and hemoglobin in biological fluids.</article-title>
            <source>Ann Clin Lab Sci</source>
            <year>1980</year>
            <season>Nov-Dec</season>
            <volume>10</volume>
            <issue>6</issue>
            <fpage>493</fpage>
            <page-range>493-9</page-range>
            <pub-id pub-id-type="pmid">7447391</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cohen</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>RS</given-names>
              </name>
            </person-group>
            <article-title>Clinical practice. Microscopic hematuria.</article-title>
            <source>N Engl J Med</source>
            <year>2003</year>
            <month>Jun</month>
            <day>05</day>
            <volume>348</volume>
            <issue>23</issue>
            <fpage>2330</fpage>
            <page-range>2330-8</page-range>
            <pub-id pub-id-type="pmid">12788998</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rao</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Gao</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Pohl</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>JS</given-names>
              </name>
            </person-group>
            <article-title>Dipstick pseudohematuria: unnecessary consultation and evaluation.</article-title>
            <source>J Urol</source>
            <year>2010</year>
            <month>Feb</month>
            <volume>183</volume>
            <issue>2</issue>
            <fpage>560</fpage>
            <page-range>560-4</page-range>
            <pub-id pub-id-type="pmid">20018314</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Froom</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ribak</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Benbassat</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Significance of microhaematuria in young adults.</article-title>
            <source>Br Med J (Clin Res Ed)</source>
            <year>1984</year>
            <month>Jan</month>
            <day>07</day>
            <volume>288</volume>
            <issue>6410</issue>
            <fpage>20</fpage>
            <page-range>20-2</page-range>
            <pub-id pub-id-type="pmid">6418299</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Armstrong</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Urinalysis in Western culture: a brief history.</article-title>
            <source>Kidney Int</source>
            <year>2007</year>
            <month>Mar</month>
            <volume>71</volume>
            <issue>5</issue>
            <fpage>384</fpage>
            <page-range>384-7</page-range>
            <pub-id pub-id-type="pmid">17191081</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ishida</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Matsuzaki</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Suzuki</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Suzuki</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kawamura</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Marunaka</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Iwami</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Association between 3-Year Repetitive Isolated Hematuria and eGFR Deterioration in an Apparently Healthy Population: A Retrospective Cohort Study.</article-title>
            <source>Int J Environ Res Public Health</source>
            <year>2022</year>
            <month>Sep</month>
            <day>12</day>
            <volume>19</volume>
            <issue>18</issue>
            <pub-id pub-id-type="pmid">36141738</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Grossfeld</surname>
                <given-names>GD</given-names>
              </name>
              <name>
                <surname>Wolf</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Litwan</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Hricak</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Shuler</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Agerter</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Carroll</surname>
                <given-names>PR</given-names>
              </name>
            </person-group>
            <article-title>Asymptomatic microscopic hematuria in adults: summary of the AUA best practice policy recommendations.</article-title>
            <source>Am Fam Physician</source>
            <year>2001</year>
            <month>Mar</month>
            <day>15</day>
            <volume>63</volume>
            <issue>6</issue>
            <fpage>1145</fpage>
            <page-range>1145-54</page-range>
            <pub-id pub-id-type="pmid">11277551</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tan</surname>
                <given-names>WS</given-names>
              </name>
              <name>
                <surname>Sarpong</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Khetrapal</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Rodney</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mostafid</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Cresswell</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hicks</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rane</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Henderson</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Watson</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Cherian</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Brew-Graves</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Feber</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kelly</surname>
                <given-names>JD</given-names>
              </name>
              <collab>DETECT I Trial Collaborators</collab>
            </person-group>
            <article-title>Can Renal and Bladder Ultrasound Replace Computerized Tomography Urogram in Patients Investigated for Microscopic Hematuria?</article-title>
            <source>J Urol</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>200</volume>
            <issue>5</issue>
            <fpage>973</fpage>
            <page-range>973-980</page-range>
            <pub-id pub-id-type="pmid">29702097</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bolenz</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Schr&#x000f6;ppel</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Eisenhardt</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Schmitz-Dr&#x000e4;ger</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Grimm</surname>
                <given-names>MO</given-names>
              </name>
            </person-group>
            <article-title>The Investigation of Hematuria.</article-title>
            <source>Dtsch Arztebl Int</source>
            <year>2018</year>
            <month>Nov</month>
            <day>30</day>
            <volume>115</volume>
            <issue>48</issue>
            <fpage>801</fpage>
            <page-range>801-807</page-range>
            <pub-id pub-id-type="pmid">30642428</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Loo</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Lieberman</surname>
                <given-names>SF</given-names>
              </name>
              <name>
                <surname>Slezak</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Landa</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Mariani</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Nicolaisen</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Aspera</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Jacobsen</surname>
                <given-names>SJ</given-names>
              </name>
            </person-group>
            <article-title>Stratifying risk of urinary tract malignant tumors in patients with asymptomatic microscopic hematuria.</article-title>
            <source>Mayo Clin Proc</source>
            <year>2013</year>
            <month>Feb</month>
            <volume>88</volume>
            <issue>2</issue>
            <fpage>129</fpage>
            <page-range>129-38</page-range>
            <pub-id pub-id-type="pmid">23312369</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wetmore</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Guo</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Collins</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Gilbertson</surname>
                <given-names>DT</given-names>
              </name>
            </person-group>
            <article-title>The incidence, prevalence, and outcomes of glomerulonephritis derived from a large retrospective analysis.</article-title>
            <source>Kidney Int</source>
            <year>2016</year>
            <month>Oct</month>
            <volume>90</volume>
            <issue>4</issue>
            <fpage>853</fpage>
            <page-range>853-60</page-range>
            <pub-id pub-id-type="pmid">27425855</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sorokin</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Mamoulakis</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Miyazawa</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Rodgers</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Talati</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lotan</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Epidemiology of stone disease across the world.</article-title>
            <source>World J Urol</source>
            <year>2017</year>
            <month>Sep</month>
            <volume>35</volume>
            <issue>9</issue>
            <fpage>1301</fpage>
            <page-range>1301-1320</page-range>
            <pub-id pub-id-type="pmid">28213860</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tandogdu</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Wagenlehner</surname>
                <given-names>FM</given-names>
              </name>
            </person-group>
            <article-title>Global epidemiology of urinary tract infections.</article-title>
            <source>Curr Opin Infect Dis</source>
            <year>2016</year>
            <month>Feb</month>
            <volume>29</volume>
            <issue>1</issue>
            <fpage>73</fpage>
            <page-range>73-9</page-range>
            <pub-id pub-id-type="pmid">26694621</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kranz</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Schmidt</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lebert</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Schneidewind</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Mandraka</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Kunze</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Helbig</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Vahlensieck</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Naber</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Schmiemann</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Wagenlehner</surname>
                <given-names>FM</given-names>
              </name>
            </person-group>
            <article-title>The 2017 Update of the German Clinical Guideline on Epidemiology, Diagnostics, Therapy, Prevention, and Management of Uncomplicated Urinary Tract Infections in Adult Patients. Part II: Therapy and Prevention.</article-title>
            <source>Urol Int</source>
            <year>2018</year>
            <volume>100</volume>
            <issue>3</issue>
            <fpage>271</fpage>
            <page-range>271-278</page-range>
            <pub-id pub-id-type="pmid">29539622</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Berry</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Coffey</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Walsh</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Ewing</surname>
                <given-names>LL</given-names>
              </name>
            </person-group>
            <article-title>The development of human benign prostatic hyperplasia with age.</article-title>
            <source>J Urol</source>
            <year>1984</year>
            <month>Sep</month>
            <volume>132</volume>
            <issue>3</issue>
            <fpage>474</fpage>
            <page-range>474-9</page-range>
            <pub-id pub-id-type="pmid">6206240</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Platz</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Joshu</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Mondul</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Peskoe</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Willett</surname>
                <given-names>WC</given-names>
              </name>
              <name>
                <surname>Giovannucci</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Incidence and progression of lower urinary tract symptoms in a large prospective cohort of United States men.</article-title>
            <source>J Urol</source>
            <year>2012</year>
            <month>Aug</month>
            <volume>188</volume>
            <issue>2</issue>
            <fpage>496</fpage>
            <page-range>496-501</page-range>
            <pub-id pub-id-type="pmid">22704110</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Loeb</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kettermann</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Carter</surname>
                <given-names>HB</given-names>
              </name>
              <name>
                <surname>Ferrucci</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Metter</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Walsh</surname>
                <given-names>PC</given-names>
              </name>
            </person-group>
            <article-title>Prostate volume changes over time: results from the Baltimore Longitudinal Study of Aging.</article-title>
            <source>J Urol</source>
            <year>2009</year>
            <month>Oct</month>
            <volume>182</volume>
            <issue>4</issue>
            <fpage>1458</fpage>
            <page-range>1458-62</page-range>
            <pub-id pub-id-type="pmid">19683305</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wei</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Calhoun</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Jacobsen</surname>
                <given-names>SJ</given-names>
              </name>
            </person-group>
            <article-title>Urologic diseases in America project: benign prostatic hyperplasia.</article-title>
            <source>J Urol</source>
            <year>2005</year>
            <month>Apr</month>
            <volume>173</volume>
            <issue>4</issue>
            <fpage>1256</fpage>
            <page-range>1256-61</page-range>
            <pub-id pub-id-type="pmid">15758764</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r26">
          <label>26</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Mahboob</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rout</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Leslie</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Bokhari</surname>
                <given-names>SRA</given-names>
              </name>
            </person-group>
            <chapter-title>Autosomal Dominant Polycystic Kidney Disease</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2024</year>
            <month>3</month>
            <day>20</day>
            <pub-id pub-id-type="pmid">30422529</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r27">
          <label>27</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Singh</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sookraj</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <chapter-title>Kidney Trauma</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>7</month>
            <day>17</day>
            <pub-id pub-id-type="pmid">30422491</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aziz</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Bugaev</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Baltazar</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Haines</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yeung</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Posluszny</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Como</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Freeman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kasotakis</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Management of adult renal trauma: a practice management guideline from the eastern association for the surgery of trauma.</article-title>
            <source>BMC Surg</source>
            <year>2023</year>
            <month>Jan</month>
            <day>27</day>
            <volume>23</volume>
            <issue>1</issue>
            <fpage>22</fpage>
            <pub-id pub-id-type="pmid">36707832</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Granata</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Distefano</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Sturiale</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Figuera</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Foti</surname>
                <given-names>PV</given-names>
              </name>
              <name>
                <surname>Palmucci</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Basile</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>From Nutcracker Phenomenon to Nutcracker Syndrome: A Pictorial Review.</article-title>
            <source>Diagnostics (Basel)</source>
            <year>2021</year>
            <month>Jan</month>
            <day>11</day>
            <volume>11</volume>
            <issue>1</issue>
            <pub-id pub-id-type="pmid">33440614</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r30">
          <label>30</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Penfold</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Leslie</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Lotfollahzadeh</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <chapter-title>Nutcracker Syndrome and Left Renal Vein Entrapment</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2024</year>
            <month>5</month>
            <day>7</day>
            <pub-id pub-id-type="pmid">32644615</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bignall</surname>
                <given-names>ONR</given-names>
              </name>
              <name>
                <surname>Dixon</surname>
                <given-names>BP</given-names>
              </name>
            </person-group>
            <article-title>Management of Hematuria in Children.</article-title>
            <source>Curr Treat Options Pediatr</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>4</volume>
            <issue>3</issue>
            <fpage>333</fpage>
            <page-range>333-349</page-range>
            <pub-id pub-id-type="pmid">30128264</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gregorio</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Caparali</surname>
                <given-names>EB</given-names>
              </name>
              <name>
                <surname>Shojaei</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ricardo</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Barua</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Alport Syndrome: Clinical Spectrum and Therapeutic Advances.</article-title>
            <source>Kidney Med</source>
            <year>2023</year>
            <month>May</month>
            <volume>5</volume>
            <issue>5</issue>
            <fpage>100631</fpage>
            <pub-id pub-id-type="pmid">37122389</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r33">
          <label>33</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Rout</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>DeVrieze</surname>
                <given-names>BW</given-names>
              </name>
            </person-group>
            <chapter-title>Goodpasture Syndrome</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2024</year>
            <month>6</month>
            <day>1</day>
            <pub-id pub-id-type="pmid">29083697</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r34">
          <label>34</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Mangla</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ehsan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Agarwal</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Maruvada</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <chapter-title>Sickle Cell Anemia</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>9</month>
            <day>4</day>
            <pub-id pub-id-type="pmid">29489205</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r35">
          <label>35</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Sedrak</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kondamudi</surname>
                <given-names>NP</given-names>
              </name>
            </person-group>
            <chapter-title>Sickle Cell Disease (Archived)</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>8</month>
            <day>28</day>
            <pub-id pub-id-type="pmid">29494006</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ataga</surname>
                <given-names>KI</given-names>
              </name>
              <name>
                <surname>Saraf</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Derebail</surname>
                <given-names>VK</given-names>
              </name>
            </person-group>
            <article-title>The nephropathy of sickle cell trait and sickle cell disease.</article-title>
            <source>Nat Rev Nephrol</source>
            <year>2022</year>
            <month>Jun</month>
            <volume>18</volume>
            <issue>6</issue>
            <fpage>361</fpage>
            <page-range>361-377</page-range>
            <pub-id pub-id-type="pmid">35190716</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Khadra</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Pickard</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Charlton</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Powell</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>Neal</surname>
                <given-names>DE</given-names>
              </name>
            </person-group>
            <article-title>A prospective analysis of 1,930 patients with hematuria to evaluate current diagnostic practice.</article-title>
            <source>J Urol</source>
            <year>2000</year>
            <month>Feb</month>
            <volume>163</volume>
            <issue>2</issue>
            <fpage>524</fpage>
            <page-range>524-7</page-range>
            <pub-id pub-id-type="pmid">10647670</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jeong</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Byun</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>SE</given-names>
              </name>
            </person-group>
            <article-title>No increase in risk of microscopic hematuria with aspirin use by asymptomatic healthy people.</article-title>
            <source>JAMA Intern Med</source>
            <year>2013</year>
            <month>Jun</month>
            <day>24</day>
            <volume>173</volume>
            <issue>12</issue>
            <fpage>1145</fpage>
            <page-range>1145-6</page-range>
            <pub-id pub-id-type="pmid">23609065</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Culclasure</surname>
                <given-names>TF</given-names>
              </name>
              <name>
                <surname>Bray</surname>
                <given-names>VJ</given-names>
              </name>
              <name>
                <surname>Hasbargen</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>The significance of hematuria in the anticoagulated patient.</article-title>
            <source>Arch Intern Med</source>
            <year>1994</year>
            <month>Mar</month>
            <day>28</day>
            <volume>154</volume>
            <issue>6</issue>
            <fpage>649</fpage>
            <page-range>649-52</page-range>
            <pub-id pub-id-type="pmid">8129498</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nielsen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Qaseem</surname>
                <given-names>A</given-names>
              </name>
              <collab>High Value Care Task Force of the American College of Physicians</collab>
            </person-group>
            <article-title>Hematuria as a Marker of Occult Urinary Tract Cancer: Advice for High-Value Care From the American College of Physicians.</article-title>
            <source>Ann Intern Med</source>
            <year>2016</year>
            <month>Apr</month>
            <day>05</day>
            <volume>164</volume>
            <issue>7</issue>
            <fpage>488</fpage>
            <page-range>488-97</page-range>
            <pub-id pub-id-type="pmid">26810935</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r41">
          <label>41</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Kazi</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Hashmi</surname>
                <given-names>MF</given-names>
              </name>
            </person-group>
            <chapter-title>Glomerulonephritis</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>6</month>
            <day>26</day>
            <pub-id pub-id-type="pmid">32809479</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Anjum</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Twanabasu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Shrestha</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Urine Discoloration Associated with Metronidazole: A Case Report.</article-title>
            <source>JNMA J Nepal Med Assoc</source>
            <year>2022</year>
            <month>Nov</month>
            <day>02</day>
            <volume>60</volume>
            <issue>255</issue>
            <fpage>972</fpage>
            <page-range>972-974</page-range>
            <pub-id pub-id-type="pmid">36705176</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ghandour</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Freifeld</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Singla</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Lotan</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Evaluation of Hematuria in a Large Public Health Care System.</article-title>
            <source>Bladder Cancer</source>
            <year>2019</year>
            <volume>5</volume>
            <issue>2</issue>
            <fpage>119</fpage>
            <page-range>119-129</page-range>
            <pub-id pub-id-type="pmid">31930164</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Johnson</surname>
                <given-names>EK</given-names>
              </name>
              <name>
                <surname>Daignault</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>CT</given-names>
              </name>
            </person-group>
            <article-title>Patterns of hematuria referral to urologists: does a gender disparity exist?</article-title>
            <source>Urology</source>
            <year>2008</year>
            <month>Sep</month>
            <volume>72</volume>
            <issue>3</issue>
            <fpage>498</fpage>
            <page-range>498-502; discussion 502-3</page-range>
            <pub-id pub-id-type="pmid">18619657</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aguilar-Davidov</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Ram&#x000ed;rez-Muci&#x000f1;o</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Culebro-Garc&#x000ed;a</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sotomayor</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Castillejos-Molina</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Feria-Bernal</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Rodr&#x000ed;guez-Covarrubias</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Performance of computed tomographic urography for the detection of bladder tumors in patients with microscopic hematuria.</article-title>
            <source>Actas Urol Esp</source>
            <year>2013</year>
            <season>Jul-Aug</season>
            <volume>37</volume>
            <issue>7</issue>
            <fpage>408</fpage>
            <page-range>408-11</page-range>
            <pub-id pub-id-type="pmid">23398811</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Elias</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Svatek</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ho</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lotan</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>High-risk patients with hematuria are not evaluated according to guideline recommendations.</article-title>
            <source>Cancer</source>
            <year>2010</year>
            <month>Jun</month>
            <day>15</day>
            <volume>116</volume>
            <issue>12</issue>
            <fpage>2954</fpage>
            <page-range>2954-9</page-range>
            <pub-id pub-id-type="pmid">20564400</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Matulewicz</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Demzik</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>DeLancey</surname>
                <given-names>JO</given-names>
              </name>
              <name>
                <surname>Popescu</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Makarov</surname>
                <given-names>DV</given-names>
              </name>
              <name>
                <surname>Meeks</surname>
                <given-names>JJ</given-names>
              </name>
            </person-group>
            <article-title>Disparities in the diagnostic evaluation of microhematuriaand implications for the detection of urologic malignancy.</article-title>
            <source>Urol Oncol</source>
            <year>2019</year>
            <month>May</month>
            <volume>37</volume>
            <issue>5</issue>
            <fpage>300.e1</fpage>
            <page-range>300.e1-300.e7</page-range>
            <pub-id pub-id-type="pmid">30661870</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ordell Sundelin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jensen</surname>
                <given-names>JB</given-names>
              </name>
            </person-group>
            <article-title>Asymptomatic microscopic hematuria as a predictor of neoplasia in the urinary tract.</article-title>
            <source>Scand J Urol</source>
            <year>2017</year>
            <month>Oct</month>
            <volume>51</volume>
            <issue>5</issue>
            <fpage>373</fpage>
            <page-range>373-375</page-range>
            <pub-id pub-id-type="pmid">28644736</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Taylor</surname>
                <given-names>JI</given-names>
              </name>
              <name>
                <surname>Souter</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Barocas</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Boorjian</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Raman</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Lotan</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Diagnostic Imaging in the Evaluation of Asymptomatic Microhematuria: Systematic Review and Meta-analysis.</article-title>
            <source>J Urol</source>
            <year>2023</year>
            <month>Jun</month>
            <volume>209</volume>
            <issue>6</issue>
            <fpage>1099</fpage>
            <page-range>1099-1106</page-range>
            <pub-id pub-id-type="pmid">36883858</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r50">
          <label>50</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Li</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Leslie</surname>
                <given-names>SW</given-names>
              </name>
            </person-group>
            <chapter-title>Cystitis</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>5</month>
            <day>30</day>
            <pub-id pub-id-type="pmid">29494042</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r51">
          <label>51</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Bono</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Leslie</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Reygaert</surname>
                <given-names>WC</given-names>
              </name>
            </person-group>
            <chapter-title>Uncomplicated Urinary Tract Infections</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>11</month>
            <day>13</day>
            <pub-id pub-id-type="pmid">29261874</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r52">
          <label>52</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Lala</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Leslie</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Minter</surname>
                <given-names>DA</given-names>
              </name>
            </person-group>
            <chapter-title>Acute Cystitis</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>7</month>
            <day>10</day>
            <pub-id pub-id-type="pmid">29083726</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r53">
          <label>53</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Pandey</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Syed</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <chapter-title>Renal Cancer</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>8</month>
            <day>8</day>
            <pub-id pub-id-type="pmid">32644401</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r54">
          <label>54</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Leslie</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Soon-Sutton</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>Aeddula</surname>
                <given-names>NR</given-names>
              </name>
            </person-group>
            <chapter-title>Bladder Cancer</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2024</year>
            <month>8</month>
            <day>15</day>
            <pub-id pub-id-type="pmid">30725608</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r55">
          <label>55</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Nojaba</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Guzman</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <chapter-title>Nephrolithiasis (Kidney Stones) (Archived)</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>8</month>
            <day>8</day>
            <pub-id pub-id-type="pmid">32644653</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r56">
          <label>56</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Patti</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Leslie</surname>
                <given-names>SW</given-names>
              </name>
            </person-group>
            <chapter-title>Acute Renal Colic</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2024</year>
            <month>6</month>
            <day>6</day>
            <pub-id pub-id-type="pmid">28613743</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r57">
          <label>57</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Thakore</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Liang</surname>
                <given-names>TH</given-names>
              </name>
            </person-group>
            <chapter-title>Urolithiasis</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>6</month>
            <day>5</day>
            <pub-id pub-id-type="pmid">32644527</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r58">
          <label>58</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Ng</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Leslie</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Baradhi</surname>
                <given-names>KM</given-names>
              </name>
            </person-group>
            <chapter-title>Benign Prostatic Hyperplasia</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2024</year>
            <month>1</month>
            <day>11</day>
            <pub-id pub-id-type="pmid">32644346</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r59">
          <label>59</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Phillips</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Holzmer</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Turco</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Mirzaie</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mause</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Mause</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Person</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Leslie</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Cornell</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Wagner</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bertellotti</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Asensio</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Trauma to the bladder and ureter: a review of diagnosis, management, and prognosis.</article-title>
            <source>Eur J Trauma Emerg Surg</source>
            <year>2017</year>
            <month>Dec</month>
            <volume>43</volume>
            <issue>6</issue>
            <fpage>763</fpage>
            <page-range>763-773</page-range>
            <pub-id pub-id-type="pmid">28730297</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r60">
          <label>60</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Tullington</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Blecker</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <chapter-title>Lower Genitourinary Trauma</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>5</month>
            <day>8</day>
            <pub-id pub-id-type="pmid">32491459</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r61">
          <label>61</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Blick</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Nazir</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Mallett</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Turney</surname>
                <given-names>BW</given-names>
              </name>
              <name>
                <surname>Onwu</surname>
                <given-names>NN</given-names>
              </name>
              <name>
                <surname>Roberts</surname>
                <given-names>IS</given-names>
              </name>
              <name>
                <surname>Crew</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Cowan</surname>
                <given-names>NC</given-names>
              </name>
            </person-group>
            <article-title>Evaluation of diagnostic strategies for bladder cancer using computed tomography (CT) urography, flexible cystoscopy and voided urine cytology: results for 778 patients from a hospital haematuria clinic.</article-title>
            <source>BJU Int</source>
            <year>2012</year>
            <month>Jul</month>
            <volume>110</volume>
            <issue>1</issue>
            <fpage>84</fpage>
            <page-range>84-94</page-range>
            <pub-id pub-id-type="pmid">22122739</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r62">
          <label>62</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Daneshmand</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lotan</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Pohar</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Trabulsi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Woods</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Downs</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>O'Donnell</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bivalacqua</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>DeCastro</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Steinberg</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kamat</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Resnick</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Konety</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Schoenberg</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>JS</given-names>
              </name>
              <collab>Flexible Blue Light Study Group Collaborators</collab>
            </person-group>
            <article-title>Efficacy and Safety of Blue Light Flexible Cystoscopy with Hexaminolevulinate in the Surveillance of Bladder Cancer: A Phase III, Comparative, Multicenter Study.</article-title>
            <source>J Urol</source>
            <year>2018</year>
            <month>May</month>
            <volume>199</volume>
            <issue>5</issue>
            <fpage>1158</fpage>
            <page-range>1158-1165</page-range>
            <pub-id pub-id-type="pmid">29203268</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r63">
          <label>63</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ke</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>UroVysion<sup>TM</sup> Fluorescence In Situ Hybridization in Urological Cancers: A Narrative Review and Future Perspectives.</article-title>
            <source>Cancers (Basel)</source>
            <year>2022</year>
            <month>Nov</month>
            <day>03</day>
            <volume>14</volume>
            <issue>21</issue>
            <pub-id pub-id-type="pmid">36358841</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r64">
          <label>64</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Takeuchi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>McDonald</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Takahashi</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Frank</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>King</surname>
                <given-names>BF</given-names>
              </name>
              <name>
                <surname>Kawashima</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Cancer Prevalence and Risk Stratification in Adults Presenting With Hematuria: A Population-Based Cohort Study.</article-title>
            <source>Mayo Clin Proc Innov Qual Outcomes</source>
            <year>2021</year>
            <month>Apr</month>
            <volume>5</volume>
            <issue>2</issue>
            <fpage>308</fpage>
            <page-range>308-319</page-range>
            <pub-id pub-id-type="pmid">33997630</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r65">
          <label>65</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tan</surname>
                <given-names>WS</given-names>
              </name>
              <name>
                <surname>Ahmad</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Feber</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mostafid</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Cresswell</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Fankhauser</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Waisbrod</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hermanns</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Sasieni</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kelly</surname>
                <given-names>JD</given-names>
              </name>
              <collab>DETECT I trial collaborators</collab>
            </person-group>
            <article-title>Development and validation of a haematuria cancer risk score to identify patients at risk of harbouring cancer.</article-title>
            <source>J Intern Med</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>285</volume>
            <issue>4</issue>
            <fpage>436</fpage>
            <page-range>436-445</page-range>
            <pub-id pub-id-type="pmid">30521125</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r66">
          <label>66</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lisanti</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Graeber</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Syed</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Moeck</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rittel</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Aden</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Schwope</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Jellison</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>What is the relative risk of urologic malignancy in microscopic hematuria patients after negative evaluation? A long-term population-based retrospective analysis of 8465 patients.</article-title>
            <source>Abdom Radiol (NY)</source>
            <year>2023</year>
            <month>Mar</month>
            <volume>48</volume>
            <issue>3</issue>
            <fpage>1011</fpage>
            <page-range>1011-1019</page-range>
            <pub-id pub-id-type="pmid">36592198</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r67">
          <label>67</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ng</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Stenzl</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vasdev</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Urinary biomarkers in bladder cancer: A review of the current landscape and future directions.</article-title>
            <source>Urol Oncol</source>
            <year>2021</year>
            <month>Jan</month>
            <volume>39</volume>
            <issue>1</issue>
            <fpage>41</fpage>
            <page-range>41-51</page-range>
            <pub-id pub-id-type="pmid">32919875</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r68">
          <label>68</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maas</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Todenh&#x000f6;fer</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Black</surname>
                <given-names>PC</given-names>
              </name>
            </person-group>
            <article-title>Urine biomarkers in bladder cancer - current status and future perspectives.</article-title>
            <source>Nat Rev Urol</source>
            <year>2023</year>
            <month>Oct</month>
            <volume>20</volume>
            <issue>10</issue>
            <fpage>597</fpage>
            <page-range>597-614</page-range>
            <pub-id pub-id-type="pmid">37225864</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r69">
          <label>69</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Koo</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Rha</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>Hong</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Chung</surname>
                <given-names>BH</given-names>
              </name>
            </person-group>
            <article-title>Diagnostic impact of dysmorphic red blood cells on evaluating microscopic hematuria: the urologist's perspective.</article-title>
            <source>Int Urol Nephrol</source>
            <year>2016</year>
            <month>Jul</month>
            <volume>48</volume>
            <issue>7</issue>
            <fpage>1021</fpage>
            <page-range>1021-7</page-range>
            <pub-id pub-id-type="pmid">27020444</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r70">
          <label>70</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schramek</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Schuster</surname>
                <given-names>FX</given-names>
              </name>
              <name>
                <surname>Georgopoulos</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Porpaczy</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Maier</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Value of urinary erythrocyte morphology in assessment of symptomless microhaematuria.</article-title>
            <source>Lancet</source>
            <year>1989</year>
            <month>Dec</month>
            <day>02</day>
            <volume>2</volume>
            <issue>8675</issue>
            <fpage>1316</fpage>
            <page-range>1316-9</page-range>
            <pub-id pub-id-type="pmid">2574263</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r71">
          <label>71</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hamadah</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Gharaibeh</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Mara</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Lieske</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Said</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nasr</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Leung</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Urinalysis for the diagnosis of glomerulonephritis: role of dysmorphic red blood cells.</article-title>
            <source>Nephrol Dial Transplant</source>
            <year>2018</year>
            <month>Aug</month>
            <day>01</day>
            <volume>33</volume>
            <issue>8</issue>
            <fpage>1397</fpage>
            <page-range>1397-1403</page-range>
            <pub-id pub-id-type="pmid">29156008</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r72">
          <label>72</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Madaio</surname>
                <given-names>MP</given-names>
              </name>
            </person-group>
            <article-title>Renal biopsy.</article-title>
            <source>Kidney Int</source>
            <year>1990</year>
            <month>Sep</month>
            <volume>38</volume>
            <issue>3</issue>
            <fpage>529</fpage>
            <page-range>529-43</page-range>
            <pub-id pub-id-type="pmid">2232496</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r73">
          <label>73</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Marchel</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Trachtman</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Larkina</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Helmuth</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lai Yee</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Fermin</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Bomback</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Canetta</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Gipson</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Mottl</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Parekh</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Saha</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Sampson</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Lafayette</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Mariani</surname>
                <given-names>LH</given-names>
              </name>
              <collab>Nephrotic Syndrome Study Network (NEPTUNE) and Cure Glomerulonephropathy (CureGN)</collab>
            </person-group>
            <article-title>The Significance of Hematuria in Podocytopathies.</article-title>
            <source>Clin J Am Soc Nephrol</source>
            <year>2024</year>
            <month>Jan</month>
            <day>01</day>
            <volume>19</volume>
            <issue>1</issue>
            <fpage>56</fpage>
            <page-range>56-66</page-range>
            <pub-id pub-id-type="pmid">37733352</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r74">
          <label>74</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brown</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Reidy</surname>
                <given-names>KJ</given-names>
              </name>
            </person-group>
            <article-title>Approach to the Child with Hematuria.</article-title>
            <source>Pediatr Clin North Am</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>66</volume>
            <issue>1</issue>
            <fpage>15</fpage>
            <page-range>15-30</page-range>
            <pub-id pub-id-type="pmid">30454740</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r75">
          <label>75</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mears</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Colemeadow</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Johal</surname>
                <given-names>NS</given-names>
              </name>
            </person-group>
            <article-title>Haematuria in children.</article-title>
            <source>Br J Hosp Med (Lond)</source>
            <year>2021</year>
            <month>May</month>
            <day>02</day>
            <volume>82</volume>
            <issue>5</issue>
            <fpage>1</fpage>
            <page-range>1-8</page-range>
            <pub-id pub-id-type="pmid">34076519</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r76">
          <label>76</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vehaskari</surname>
                <given-names>VM</given-names>
              </name>
              <name>
                <surname>Rapola</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Koskimies</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Savilahti</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Vilska</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hallman</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Microscopic hematuria in school children: epidemiology and clinicopathologic evaluation.</article-title>
            <source>J Pediatr</source>
            <year>1979</year>
            <month>Nov</month>
            <volume>95</volume>
            <issue>5 Pt 1</issue>
            <fpage>676</fpage>
            <page-range>676-84</page-range>
            <pub-id pub-id-type="pmid">490233</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r77">
          <label>77</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Roache-Robinson</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Killeen</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Hotwagner</surname>
                <given-names>DT</given-names>
              </name>
            </person-group>
            <chapter-title>IgA Vasculitis (Henoch-Sch&#x000f6;nlein Purpura)</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>9</month>
            <day>26</day>
            <pub-id pub-id-type="pmid">30725937</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r78">
          <label>78</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Liu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Thaker</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Dong</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis and Treatment for Shiga Toxin-Producing <italic>Escherichia coli</italic> Associated Hemolytic Uremic Syndrome.</article-title>
            <source>Toxins (Basel)</source>
            <year>2022</year>
            <month>Dec</month>
            <day>23</day>
            <volume>15</volume>
            <issue>1</issue>
            <pub-id pub-id-type="pmid">36668830</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r79">
          <label>79</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Michael</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bagga</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sartain</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>RJH</given-names>
              </name>
            </person-group>
            <article-title>Haemolytic uraemic syndrome.</article-title>
            <source>Lancet</source>
            <year>2022</year>
            <month>Nov</month>
            <day>12</day>
            <volume>400</volume>
            <issue>10364</issue>
            <fpage>1722</fpage>
            <page-range>1722-1740</page-range>
            <pub-id pub-id-type="pmid">36272423</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r80">
          <label>80</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Riedl Khursigara</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Matsuda-Abedini</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Radhakrishnan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hladunewich</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Lemaire</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Teoh</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Noone</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Licht</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>A Guide for Adult Nephrologists and Hematologists to Managing Atypical Hemolytic Uremic Syndrome and C3 Glomerulopathy in Teens Transitioning to Young Adults.</article-title>
            <source>Adv Chronic Kidney Dis</source>
            <year>2022</year>
            <month>May</month>
            <volume>29</volume>
            <issue>3</issue>
            <fpage>231</fpage>
            <page-range>231-242</page-range>
            <pub-id pub-id-type="pmid">36084970</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r81">
          <label>81</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Bhandari</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rout</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sedhai</surname>
                <given-names>YR</given-names>
              </name>
            </person-group>
            <chapter-title>Hemolytic Uremic Syndrome</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>10</month>
            <day>19</day>
            <pub-id pub-id-type="pmid">32310498</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r82">
          <label>82</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McIvor</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Southcott</surname>
                <given-names>RD</given-names>
              </name>
            </person-group>
            <article-title>Control of severe vesical haemorrhage by therapeutic embolisation.</article-title>
            <source>Clin Radiol</source>
            <year>1982</year>
            <month>Sep</month>
            <volume>33</volume>
            <issue>5</issue>
            <fpage>561</fpage>
            <page-range>561-7</page-range>
            <pub-id pub-id-type="pmid">7116778</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r83">
          <label>83</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>D'Amico</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Foss</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Uhr</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rudnick</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kloniecke</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Gomella</surname>
                <given-names>LG</given-names>
              </name>
            </person-group>
            <article-title>Hemorrhagic cystitis: a review of the literature and treatment options.</article-title>
            <source>Can J Urol</source>
            <year>2022</year>
            <month>Oct</month>
            <volume>29</volume>
            <issue>5</issue>
            <fpage>11276</fpage>
            <page-range>11276-11283</page-range>
            <pub-id pub-id-type="pmid">36245196</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r84">
          <label>84</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Leslie</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Chargui</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Stormont</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <chapter-title>Transurethral Resection of the Prostate</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>9</month>
            <day>4</day>
            <pub-id pub-id-type="pmid">32809719</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r85">
          <label>85</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bo</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Yangyang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Jiayuan</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Siwen</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Yong</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Junbo</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Evaluation of bladder clots using a nonsurgical treatment.</article-title>
            <source>Urology</source>
            <year>2014</year>
            <month>Feb</month>
            <volume>83</volume>
            <issue>2</issue>
            <fpage>498</fpage>
            <page-range>498-9</page-range>
            <pub-id pub-id-type="pmid">24315307</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r86">
          <label>86</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Xu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jin</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Shan</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Xue</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>A simple and effective method for bladder blood clot evacuation using hydrogen peroxide.</article-title>
            <source>J Int Med Res</source>
            <year>2020</year>
            <month>May</month>
            <volume>48</volume>
            <issue>5</issue>
            <fpage>300060520924546</fpage>
            <pub-id pub-id-type="pmid">32436454</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r87">
          <label>87</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ogita</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kawamori</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Yamashita</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Nakagawa</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Palliative radiotherapy for gross hematuria in patients with advanced cancer.</article-title>
            <source>Sci Rep</source>
            <year>2021</year>
            <month>May</month>
            <day>05</day>
            <volume>11</volume>
            <issue>1</issue>
            <fpage>9533</fpage>
            <pub-id pub-id-type="pmid">33953242</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r88">
          <label>88</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lacarri&#x000e8;re</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Smaali</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Benyoucef</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pfister</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Grise</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>The efficacy of hemostatic radiotherapy for bladder cancer-related hematuria in patients unfit for surgery.</article-title>
            <source>Int Braz J Urol</source>
            <year>2013</year>
            <season>Nov-Dec</season>
            <volume>39</volume>
            <issue>6</issue>
            <fpage>808</fpage>
            <page-range>808-16</page-range>
            <pub-id pub-id-type="pmid">24456773</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r89">
          <label>89</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yi</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Yoder</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zaner</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hirsch</surname>
                <given-names>AE</given-names>
              </name>
            </person-group>
            <article-title>Palliative radiation therapy of symptomatic recurrent bladder cancer.</article-title>
            <source>Pain Physician</source>
            <year>2007</year>
            <month>Mar</month>
            <volume>10</volume>
            <issue>2</issue>
            <fpage>285</fpage>
            <page-range>285-90</page-range>
            <pub-id pub-id-type="pmid">17387350</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r90">
          <label>90</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tey</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Soon</surname>
                <given-names>YY</given-names>
              </name>
              <name>
                <surname>Cheo</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ooi</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>Ho</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Vellayappan</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Chia</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Tai</surname>
                <given-names>BC</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of Palliative Bladder Radiotherapy for Hematuria in Advanced Bladder Cancer Using Contemporary Radiotherapy Techniques.</article-title>
            <source>In Vivo</source>
            <year>2019</year>
            <season>Nov-Dec</season>
            <volume>33</volume>
            <issue>6</issue>
            <fpage>2161</fpage>
            <page-range>2161-2167</page-range>
            <pub-id pub-id-type="pmid">31662552</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r91">
          <label>91</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Boyer</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Salama</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>WR</given-names>
              </name>
            </person-group>
            <article-title>Palliative radiotherapy for prostate cancer.</article-title>
            <source>Oncology (Williston Park)</source>
            <year>2014</year>
            <month>Apr</month>
            <volume>28</volume>
            <issue>4</issue>
            <fpage>306</fpage>
            <page-range>306-12</page-range>
            <pub-id pub-id-type="pmid">24839802</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r92">
          <label>92</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Perez</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Cosmatos</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Garcia</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Eisbruch</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Poulter</surname>
                <given-names>CA</given-names>
              </name>
            </person-group>
            <article-title>Irradiation in relapsing carcinoma of the prostate.</article-title>
            <source>Cancer</source>
            <year>1993</year>
            <month>Feb</month>
            <day>01</day>
            <volume>71</volume>
            <issue>3 Suppl</issue>
            <fpage>1110</fpage>
            <page-range>1110-22</page-range>
            <pub-id pub-id-type="pmid">7679040</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r93">
          <label>93</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aronowitz</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ding</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Yates</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zong</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zheng</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Jiang</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Yancey</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mittal</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Fitzgerald</surname>
                <given-names>TJ</given-names>
              </name>
            </person-group>
            <article-title>Stereotactic Body Radiotherapy for Palliation of Hematuria Arising From Urothelial Carcinoma of the Kidney in Unfavorable Surgical Candidates.</article-title>
            <source>Am J Clin Oncol</source>
            <year>2021</year>
            <month>May</month>
            <day>01</day>
            <volume>44</volume>
            <issue>5</issue>
            <fpage>175</fpage>
            <page-range>175-180</page-range>
            <pub-id pub-id-type="pmid">33710134</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r94">
          <label>94</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nikolaev</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Benda</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Palliative Radiation Therapy for Symptomatic Control of Inoperable Renal Cell Carcinoma.</article-title>
            <source>Urol Case Rep</source>
            <year>2016</year>
            <month>Jan</month>
            <volume>4</volume>
            <fpage>51</fpage>
            <page-range>51-2</page-range>
            <pub-id pub-id-type="pmid">26793580</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r95">
          <label>95</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Deng</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>He</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Gan</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Long</surname>
                <given-names>Z</given-names>
              </name>
            </person-group>
            <article-title>Superselective Prostate Artery Embolization for Treatment of Severe Haematuria Secondary to Rapid Progression of Treatment-Induced Neuroendocrine Prostate Cancer: A Case Report.</article-title>
            <source>Onco Targets Ther</source>
            <year>2022</year>
            <volume>15</volume>
            <fpage>67</fpage>
            <page-range>67-75</page-range>
            <pub-id pub-id-type="pmid">35082500</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r96">
          <label>96</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rodr&#x000ed;guez-Patr&#x000f3;n Rodr&#x000ed;guez</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sanz Mayayo</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>G&#x000f3;mez Garc&#x000ed;a</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Blazquez Sanchez</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sanchez Corral</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Briones Mardones</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Pozo Mengual</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Escudero Barrilero</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>[Hypogastric artery embolization as a palliative treatment for bleeding secondary to intractable bladder or prostate disease].</article-title>
            <source>Arch Esp Urol</source>
            <year>2003</year>
            <month>Mar</month>
            <volume>56</volume>
            <issue>2</issue>
            <fpage>111</fpage>
            <page-range>111-8</page-range>
            <pub-id pub-id-type="pmid">12731436</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r97">
          <label>97</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jefferson</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>Linder</surname>
                <given-names>BJ</given-names>
              </name>
            </person-group>
            <article-title>Hemorrhagic Cystitis: Making Rapid and Shrewd Clinical and Surgical Decisions for Improving Patient Outcomes.</article-title>
            <source>Res Rep Urol</source>
            <year>2023</year>
            <volume>15</volume>
            <fpage>291</fpage>
            <page-range>291-303</page-range>
            <pub-id pub-id-type="pmid">37404838</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r98">
          <label>98</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Marchioni</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>DE Francesco</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Campi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Carbonara</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Ferro</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Schips</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Rivas</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Papalia</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Scarpa</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Esperto</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Current management of radiation cystitis after pelvic radiotherapy: a systematic review.</article-title>
            <source>Minerva Urol Nephrol</source>
            <year>2022</year>
            <month>Jun</month>
            <volume>74</volume>
            <issue>3</issue>
            <fpage>281</fpage>
            <page-range>281-291</page-range>
            <pub-id pub-id-type="pmid">34714035</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r99">
          <label>99</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Westerman</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Boorjian</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Linder</surname>
                <given-names>BJ</given-names>
              </name>
            </person-group>
            <article-title>Safety and efficacy of intravesical alum for intractable hemorrhagic cystitis: A contemporary evaluation.</article-title>
            <source>Int Braz J Urol</source>
            <year>2016</year>
            <season>Nov-Dec</season>
            <volume>42</volume>
            <issue>6</issue>
            <fpage>1144</fpage>
            <page-range>1144-1149</page-range>
            <pub-id pub-id-type="pmid">27509371</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r100">
          <label>100</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Donahue</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Frank</surname>
                <given-names>IN</given-names>
              </name>
            </person-group>
            <article-title>Intravesical formalin for hemorrhagic cystitis: analysis of therapy.</article-title>
            <source>J Urol</source>
            <year>1989</year>
            <month>Apr</month>
            <volume>141</volume>
            <issue>4</issue>
            <fpage>809</fpage>
            <page-range>809-12</page-range>
            <pub-id pub-id-type="pmid">2648027</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r101">
          <label>101</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ferrie</surname>
                <given-names>BG</given-names>
              </name>
              <name>
                <surname>Rundle</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Kirk</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Paterson</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Scott</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Intravesical formalin in intractable haematuria.</article-title>
            <source>J Urol (Paris)</source>
            <year>1985</year>
            <volume>91</volume>
            <issue>1</issue>
            <fpage>33</fpage>
            <page-range>33-5</page-range>
            <pub-id pub-id-type="pmid">2413134</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r102">
          <label>102</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ziegelmann</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Boorjian</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Joyce</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Montgomery</surname>
                <given-names>BD</given-names>
              </name>
              <name>
                <surname>Linder</surname>
                <given-names>BJ</given-names>
              </name>
            </person-group>
            <article-title>Intravesical formalin for hemorrhagic cystitis: A contemporary cohort.</article-title>
            <source>Can Urol Assoc J</source>
            <year>2017</year>
            <season>Mar-Apr</season>
            <volume>11</volume>
            <issue>3-4</issue>
            <fpage>E79</fpage>
            <page-range>E79-E82</page-range>
            <pub-id pub-id-type="pmid">28360951</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r103">
          <label>103</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Horan</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Cooper</surname>
                <given-names>JS</given-names>
              </name>
            </person-group>
            <chapter-title>Radiation Cystitis and Hyperbaric Management</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>7</month>
            <day>17</day>
            <pub-id pub-id-type="pmid">29261976</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r104">
          <label>104</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pascoe</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Duncan</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lamb</surname>
                <given-names>BW</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>NF</given-names>
              </name>
              <name>
                <surname>Lynch</surname>
                <given-names>TH</given-names>
              </name>
              <name>
                <surname>Murphy</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Lawrentschuk</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Current management of radiation cystitis: a review and practical guide to clinical management.</article-title>
            <source>BJU Int</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>123</volume>
            <issue>4</issue>
            <fpage>585</fpage>
            <page-range>585-594</page-range>
            <pub-id pub-id-type="pmid">30113758</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r105">
          <label>105</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Sabih</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Leslie</surname>
                <given-names>SW</given-names>
              </name>
            </person-group>
            <chapter-title>Complicated Urinary Tract Infections</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>11</month>
            <day>12</day>
            <pub-id pub-id-type="pmid">28613784</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r106">
          <label>106</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Leslie</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Nelson</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Baker</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <chapter-title>Urethral Injury</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>7</month>
            <day>24</day>
            <pub-id pub-id-type="pmid">32119462</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r107">
          <label>107</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bansal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Arora</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Transurethral Resection of Prostate and Bleeding: A Prospective, Randomized, Double-Blind Placebo-Controlled Trial to See the Efficacy of Short-Term Use of Finasteride and Dutasteride on Operative Blood Loss and Prostatic Microvessel Density.</article-title>
            <source>J Endourol</source>
            <year>2017</year>
            <month>Sep</month>
            <volume>31</volume>
            <issue>9</issue>
            <fpage>910</fpage>
            <page-range>910-917</page-range>
            <pub-id pub-id-type="pmid">28650680</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r108">
          <label>108</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Salisbury</surname>
                <given-names>BH</given-names>
              </name>
              <name>
                <surname>Leslie</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Tadi</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <chapter-title>5&#x003b1;-Reductase Inhibitors</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2024</year>
            <month>6</month>
            <day>8</day>
            <pub-id pub-id-type="pmid">32310390</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r109">
          <label>109</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Coll</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Varanelli</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>RC</given-names>
              </name>
            </person-group>
            <article-title>Relationship of spontaneous passage of ureteral calculi to stone size and location as revealed by unenhanced helical CT.</article-title>
            <source>AJR Am J Roentgenol</source>
            <year>2002</year>
            <month>Jan</month>
            <volume>178</volume>
            <issue>1</issue>
            <fpage>101</fpage>
            <page-range>101-3</page-range>
            <pub-id pub-id-type="pmid">11756098</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r110">
          <label>110</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Khan</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Pearle</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Robertson</surname>
                <given-names>WG</given-names>
              </name>
              <name>
                <surname>Gambaro</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Canales</surname>
                <given-names>BK</given-names>
              </name>
              <name>
                <surname>Doizi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Traxer</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Tiselius</surname>
                <given-names>HG</given-names>
              </name>
            </person-group>
            <article-title>Kidney stones.</article-title>
            <source>Nat Rev Dis Primers</source>
            <year>2016</year>
            <month>Feb</month>
            <day>25</day>
            <volume>2</volume>
            <fpage>16008</fpage>
            <pub-id pub-id-type="pmid">27188687</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r111">
          <label>111</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mondal</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Viswanathan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sreenivasan Kodakkattil</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Percutaneous Nephrostomy in Complicated Urinary Tract Infections.</article-title>
            <source>Cureus</source>
            <year>2022</year>
            <month>Jul</month>
            <volume>14</volume>
            <issue>7</issue>
            <fpage>e26682</fpage>
            <pub-id pub-id-type="pmid">35949777</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r112">
          <label>112</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>An&#x00131;l</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>&#x0015e;ener</surname>
                <given-names>NC</given-names>
              </name>
              <name>
                <surname>Karam&#x00131;k</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Erol</surname>
                <given-names>&#x00130;</given-names>
              </name>
              <name>
                <surname>Vuru&#x0015f;kan</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Er&#x000e7;il</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>G&#x000fc;rb&#x000fc;z</surname>
                <given-names>ZG</given-names>
              </name>
            </person-group>
            <article-title>Comparison of Percutaneous Nephrostomy and Ureteral DJ Stent in Patients with Obstructive Pyelonephritis: A Retrospective Cohort Study.</article-title>
            <source>J Invest Surg</source>
            <year>2022</year>
            <month>Jul</month>
            <volume>35</volume>
            <issue>7</issue>
            <fpage>1445</fpage>
            <page-range>1445-1450</page-range>
            <pub-id pub-id-type="pmid">35414347</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r113">
          <label>113</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Garfield</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>LaGrange</surname>
                <given-names>CA</given-names>
              </name>
            </person-group>
            <chapter-title>Renal Cell Cancer</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>7</month>
            <day>31</day>
            <pub-id pub-id-type="pmid">29261992</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r114">
          <label>114</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Shamam</surname>
                <given-names>YM</given-names>
              </name>
              <name>
                <surname>Leslie</surname>
                <given-names>SW</given-names>
              </name>
            </person-group>
            <chapter-title>Renal Angiomyolipoma</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2024</year>
            <month>5</month>
            <day>2</day>
            <pub-id pub-id-type="pmid">36256751</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r115">
          <label>115</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Williams</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Lynch</surname>
                <given-names>DT</given-names>
              </name>
            </person-group>
            <chapter-title>Renal Oncocytoma</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>8</month>
            <day>28</day>
            <pub-id pub-id-type="pmid">30725948</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r116">
          <label>116</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tachibana</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ikeda</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Shimura</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Amano</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Murakami</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yamada</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Koguchi</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Maeyama</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kawamura</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sakata</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Hagiwara</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Matsumoto</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Iwamura</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of Intravesical Instillation Therapy with Low-Dose Tokyo-172 Bacillus Calmette-Gu&#x000e9;rin to Prevent Recurrence of Non-Muscle-Invasive Bladder Cancer and Treat Carcinoma in situ: A Multi-Institutional Retrospective Study.</article-title>
            <source>Urol Int</source>
            <year>2023</year>
            <volume>107</volume>
            <issue>3</issue>
            <fpage>230</fpage>
            <page-range>230-238</page-range>
            <pub-id pub-id-type="pmid">36646046</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r117">
          <label>117</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chang</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Bochner</surname>
                <given-names>BH</given-names>
              </name>
              <name>
                <surname>Chou</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Dreicer</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kamat</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Lerner</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Lotan</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Meeks</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Michalski</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Morgan</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Quale</surname>
                <given-names>DZ</given-names>
              </name>
              <name>
                <surname>Rosenberg</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Zietman</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Holzbeierlein</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline.</article-title>
            <source>J Urol</source>
            <year>2017</year>
            <month>Sep</month>
            <volume>198</volume>
            <issue>3</issue>
            <fpage>552</fpage>
            <page-range>552-559</page-range>
            <pub-id pub-id-type="pmid">28456635</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r118">
          <label>118</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lv</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Perkovic</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Ma</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Woodward</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Levin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>H</given-names>
              </name>
              <collab>TESTING Study Group</collab>
            </person-group>
            <article-title>Corticosteroid therapy in IgA nephropathy.</article-title>
            <source>J Am Soc Nephrol</source>
            <year>2012</year>
            <month>Jun</month>
            <volume>23</volume>
            <issue>6</issue>
            <fpage>1108</fpage>
            <page-range>1108-16</page-range>
            <pub-id pub-id-type="pmid">22539830</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r119">
          <label>119</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Tapia</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bashir</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <chapter-title>Nephrotic Syndrome</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>5</month>
            <day>29</day>
            <pub-id pub-id-type="pmid">29262216</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r120">
          <label>120</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Watson</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Padala</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Hashmi</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Bush</surname>
                <given-names>JS</given-names>
              </name>
            </person-group>
            <chapter-title>Alport Syndrome</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>8</month>
            <day>14</day>
            <pub-id pub-id-type="pmid">29262041</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r121">
          <label>121</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kashtan</surname>
                <given-names>CE</given-names>
              </name>
            </person-group>
            <article-title>Alport Syndrome: Achieving Early Diagnosis and Treatment.</article-title>
            <source>Am J Kidney Dis</source>
            <year>2021</year>
            <month>Feb</month>
            <volume>77</volume>
            <issue>2</issue>
            <fpage>272</fpage>
            <page-range>272-279</page-range>
            <pub-id pub-id-type="pmid">32712016</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r122">
          <label>122</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Warady</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Agarwal</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bangalore</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Chapman</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Levin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Stenvinkel</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Toto</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Chertow</surname>
                <given-names>GM</given-names>
              </name>
            </person-group>
            <article-title>Alport Syndrome Classification and Management.</article-title>
            <source>Kidney Med</source>
            <year>2020</year>
            <season>Sep-Oct</season>
            <volume>2</volume>
            <issue>5</issue>
            <fpage>639</fpage>
            <page-range>639-649</page-range>
            <pub-id pub-id-type="pmid">33094278</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r123">
          <label>123</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gross</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>T&#x000f6;nshoff</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Weber</surname>
                <given-names>LT</given-names>
              </name>
              <name>
                <surname>Pape</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Latta</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Fehrenbach</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Lange-Sperandio</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Zappel</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hoyer</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Staude</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>K&#x000f6;nig</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>John</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Gellermann</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hoppe</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Galiano</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hoecker</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Ehren</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lerch</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kashtan</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Harden</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Boeckhaus</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Friede</surname>
                <given-names>T</given-names>
              </name>
              <collab>German Pediatric Nephrology (GPN) Study Group and EARLY PRO-TECT Alport Investigators</collab>
            </person-group>
            <article-title>A multicenter, randomized, placebo-controlled, double-blind phase 3 trial with open-arm comparison indicates safety and efficacy of nephroprotective therapy with ramipril in children with Alport's syndrome.</article-title>
            <source>Kidney Int</source>
            <year>2020</year>
            <month>Jun</month>
            <volume>97</volume>
            <issue>6</issue>
            <fpage>1275</fpage>
            <page-range>1275-1286</page-range>
            <pub-id pub-id-type="pmid">32299679</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r124">
          <label>124</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Funk</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Miner</surname>
                <given-names>JH</given-names>
              </name>
            </person-group>
            <article-title>Alport syndrome and Pierson syndrome: Diseases of the glomerular basement membrane.</article-title>
            <source>Matrix Biol</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>71-72</volume>
            <fpage>250</fpage>
            <page-range>250-261</page-range>
            <pub-id pub-id-type="pmid">29673759</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r125">
          <label>125</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lionel</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Joseph</surname>
                <given-names>LK</given-names>
              </name>
              <name>
                <surname>Simon</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Pierson syndrome - a rare cause of congenital nephrotic syndrome.</article-title>
            <source>Indian J Pediatr</source>
            <year>2014</year>
            <month>Dec</month>
            <volume>81</volume>
            <issue>12</issue>
            <fpage>1416</fpage>
            <page-range>1416-7</page-range>
            <pub-id pub-id-type="pmid">24944146</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r126">
          <label>126</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Subramanian</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Leslie</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Ahmad</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <chapter-title>Autosomal Recessive Polycystic Kidney Disease</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2024</year>
            <month>3</month>
            <day>3</day>
            <pub-id pub-id-type="pmid">30725822</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r127">
          <label>127</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tryggvason</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Patrakka</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Thin basement membrane nephropathy.</article-title>
            <source>J Am Soc Nephrol</source>
            <year>2006</year>
            <month>Mar</month>
            <volume>17</volume>
            <issue>3</issue>
            <fpage>813</fpage>
            <page-range>813-22</page-range>
            <pub-id pub-id-type="pmid">16467446</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r128">
          <label>128</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dische</surname>
                <given-names>FE</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>VE</given-names>
              </name>
              <name>
                <surname>Keane</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Taube</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Bewick</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Parsons</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Incidence of thin membrane nephropathy: morphometric investigation of a population sample.</article-title>
            <source>J Clin Pathol</source>
            <year>1990</year>
            <month>Jun</month>
            <volume>43</volume>
            <issue>6</issue>
            <fpage>457</fpage>
            <page-range>457-60</page-range>
            <pub-id pub-id-type="pmid">2380394</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r129">
          <label>129</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cosio</surname>
                <given-names>FG</given-names>
              </name>
              <name>
                <surname>Falkenhain</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Sedmak</surname>
                <given-names>DD</given-names>
              </name>
            </person-group>
            <article-title>Association of thin glomerular basement membrane with other glomerulopathies.</article-title>
            <source>Kidney Int</source>
            <year>1994</year>
            <month>Aug</month>
            <volume>46</volume>
            <issue>2</issue>
            <fpage>471</fpage>
            <page-range>471-4</page-range>
            <pub-id pub-id-type="pmid">7967360</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r130">
          <label>130</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Voskarides</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Damianou</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Neocleous</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Zouvani</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Christodoulidou</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hadjiconstantinou</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Ioannou</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Athanasiou</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Patsias</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Alexopoulos</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Pierides</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kyriacou</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Deltas</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>COL4A3/COL4A4 mutations producing focal segmental glomerulosclerosis and renal failure in thin basement membrane nephropathy.</article-title>
            <source>J Am Soc Nephrol</source>
            <year>2007</year>
            <month>Nov</month>
            <volume>18</volume>
            <issue>11</issue>
            <fpage>3004</fpage>
            <page-range>3004-16</page-range>
            <pub-id pub-id-type="pmid">17942953</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r131">
          <label>131</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Buzza</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>YY</given-names>
              </name>
              <name>
                <surname>Dagher</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Babon</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Cotton</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Powell</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Dowling</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Savige</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>COL4A4 mutation in thin basement membrane disease previously described in Alport syndrome.</article-title>
            <source>Kidney Int</source>
            <year>2001</year>
            <month>Aug</month>
            <volume>60</volume>
            <issue>2</issue>
            <fpage>480</fpage>
            <page-range>480-3</page-range>
            <pub-id pub-id-type="pmid">11473630</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r132">
          <label>132</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lemmink</surname>
                <given-names>HH</given-names>
              </name>
              <name>
                <surname>Nillesen</surname>
                <given-names>WN</given-names>
              </name>
              <name>
                <surname>Mochizuki</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Schr&#x000f6;der</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Brunner</surname>
                <given-names>HG</given-names>
              </name>
              <name>
                <surname>van Oost</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Monnens</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Smeets</surname>
                <given-names>HJ</given-names>
              </name>
            </person-group>
            <article-title>Benign familial hematuria due to mutation of the type IV collagen alpha4 gene.</article-title>
            <source>J Clin Invest</source>
            <year>1996</year>
            <month>Sep</month>
            <day>01</day>
            <volume>98</volume>
            <issue>5</issue>
            <fpage>1114</fpage>
            <page-range>1114-8</page-range>
            <pub-id pub-id-type="pmid">8787673</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r133">
          <label>133</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Plevov&#x000e1;</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Gut</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Janda</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Familial hematuria: A review.</article-title>
            <source>Medicina (Kaunas)</source>
            <year>2017</year>
            <volume>53</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-10</page-range>
            <pub-id pub-id-type="pmid">28236514</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r134">
          <label>134</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Ramakrishnan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Leslie</surname>
                <given-names>SW</given-names>
              </name>
            </person-group>
            <chapter-title>Thin Basement Membrane Nephropathy</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2024</year>
            <month>8</month>
            <day>31</day>
            <pub-id pub-id-type="pmid">37603625</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r135">
          <label>135</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alchi</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Jayne</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Membranoproliferative glomerulonephritis.</article-title>
            <source>Pediatr Nephrol</source>
            <year>2010</year>
            <month>Aug</month>
            <volume>25</volume>
            <issue>8</issue>
            <fpage>1409</fpage>
            <page-range>1409-18</page-range>
            <pub-id pub-id-type="pmid">19908070</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r136">
          <label>136</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kattah</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Fervenza</surname>
                <given-names>FC</given-names>
              </name>
              <name>
                <surname>Roccatello</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Rituximab-based novel strategies for the treatment of immune-mediated glomerular diseases.</article-title>
            <source>Autoimmun Rev</source>
            <year>2013</year>
            <month>Jun</month>
            <volume>12</volume>
            <issue>8</issue>
            <fpage>854</fpage>
            <page-range>854-9</page-range>
            <pub-id pub-id-type="pmid">23000633</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r137">
          <label>137</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Qasim</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>JB</given-names>
              </name>
            </person-group>
            <chapter-title>ANCA-Associated Vasculitis</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2024</year>
            <month>8</month>
            <day>31</day>
            <pub-id pub-id-type="pmid">32119259</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r138">
          <label>138</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Rout</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Limaiem</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Hashmi</surname>
                <given-names>MF</given-names>
              </name>
            </person-group>
            <chapter-title>IgA Nephropathy (Berger Disease)</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2024</year>
            <month>4</month>
            <day>22</day>
            <pub-id pub-id-type="pmid">30855802</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r139">
          <label>139</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Tashakkorinia</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Muco</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Tudor</surname>
                <given-names>ME</given-names>
              </name>
            </person-group>
            <chapter-title>Berger Disease (Archived)</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>2</month>
            <day>6</day>
            <pub-id pub-id-type="pmid">29763174</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r140">
          <label>140</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Parmar</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Bashir</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <chapter-title>Crescentic Glomerulonephritis (Archived)</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>2</month>
            <day>20</day>
            <pub-id pub-id-type="pmid">28613478</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r141">
          <label>141</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Musa</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Brent</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Qurie</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <chapter-title>Lupus Nephritis</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>7</month>
            <day>31</day>
            <pub-id pub-id-type="pmid">29762992</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r142">
          <label>142</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Ikhlas</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Anjum</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <chapter-title>Diffuse Proliferative Glomerulonephritis</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>5</month>
            <day>8</day>
            <pub-id pub-id-type="pmid">32644412</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r143">
          <label>143</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Syeda</surname>
                <given-names>UA</given-names>
              </name>
              <name>
                <surname>Singer</surname>
                <given-names>NG</given-names>
              </name>
              <name>
                <surname>Magrey</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Anti-glomerular basement membrane antibody disease treated with rituximab: A case-based review.</article-title>
            <source>Semin Arthritis Rheum</source>
            <year>2013</year>
            <month>Jun</month>
            <volume>42</volume>
            <issue>6</issue>
            <fpage>567</fpage>
            <page-range>567-72</page-range>
            <pub-id pub-id-type="pmid">23352254</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r144">
          <label>144</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Havrda</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>[Glomerulonephritides associated with infections].</article-title>
            <source>Vnitr Lek</source>
            <year>2022</year>
            <season>Fall</season>
            <volume>68</volume>
            <issue>7</issue>
            <fpage>432</fpage>
            <page-range>432-437</page-range>
            <pub-id pub-id-type="pmid">36402567</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r145">
          <label>145</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ozkok</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Yildiz</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Hepatitis C virus associated glomerulopathies.</article-title>
            <source>World J Gastroenterol</source>
            <year>2014</year>
            <month>Jun</month>
            <day>28</day>
            <volume>20</volume>
            <issue>24</issue>
            <fpage>7544</fpage>
            <page-range>7544-54</page-range>
            <pub-id pub-id-type="pmid">24976695</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r146">
          <label>146</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wiggins</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Deliwala</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Banno</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Knight</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Minaudo</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Acute Renal Failure and Nephrotic Syndrome Secondary to Collapsing Glomerulopathy Associated With Hepatitis C.</article-title>
            <source>Cureus</source>
            <year>2022</year>
            <month>Mar</month>
            <volume>14</volume>
            <issue>3</issue>
            <fpage>e23175</fpage>
            <pub-id pub-id-type="pmid">35444880</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r147">
          <label>147</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shahab</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Golabi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Younossi</surname>
                <given-names>ZM</given-names>
              </name>
            </person-group>
            <article-title>Chronic kidney disease in patients with chronic hepatitis C virus infection.</article-title>
            <source>Minerva Gastroenterol Dietol</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>64</volume>
            <issue>4</issue>
            <fpage>376</fpage>
            <page-range>376-382</page-range>
            <pub-id pub-id-type="pmid">29327821</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r148">
          <label>148</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Bhandari</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Awais</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Aeddula</surname>
                <given-names>NR</given-names>
              </name>
            </person-group>
            <chapter-title>Cryoglobulinemia</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2024</year>
            <month>6</month>
            <day>7</day>
            <pub-id pub-id-type="pmid">32491538</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r149">
          <label>149</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Couser</surname>
                <given-names>WG</given-names>
              </name>
            </person-group>
            <article-title>Primary Membranous Nephropathy.</article-title>
            <source>Clin J Am Soc Nephrol</source>
            <year>2017</year>
            <month>Jun</month>
            <day>07</day>
            <volume>12</volume>
            <issue>6</issue>
            <fpage>983</fpage>
            <page-range>983-997</page-range>
            <pub-id pub-id-type="pmid">28550082</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r150">
          <label>150</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Moroni</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ponticelli</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Secondary Membranous Nephropathy. A Narrative Review.</article-title>
            <source>Front Med (Lausanne)</source>
            <year>2020</year>
            <volume>7</volume>
            <fpage>611317</fpage>
            <pub-id pub-id-type="pmid">33344486</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r151">
          <label>151</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Alok</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Yadav</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <chapter-title>Membranous Nephropathy</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>6</month>
            <day>5</day>
            <pub-id pub-id-type="pmid">32644595</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22710.r152">
          <label>152</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Rawla</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Padala</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Ludhwani</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <chapter-title>Poststreptococcal Glomerulonephritis</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2022</year>
            <month>10</month>
            <day>9</day>
            <pub-id pub-id-type="pmid">30855843</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
